NantHealth (NHIQ) 10-Q 8 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 08, 2020
Document And Entity Information [Abstract]
Entity Registrant Name	NantHealth, Inc.
Document Type	10-Q
Entity Central Index Key	0001566469
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		110,619,678
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Ex Transition Period	true
Entity Shell Company	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 47,478	$ 5,243
Accounts receivable, net	6,816	6,179
Related party receivables, net	657	823
Prepaid expenses and other current assets	3,680	19,341
Current assets of discontinued operation	0	6,327
Total current assets	58,631	37,913
Property, plant, and equipment, net	13,755	14,985
Goodwill	97,307	97,307
Intangible assets, net	49,838	51,848
Investment in related party	29,918	31,702
Related party receivable, net of current	1,274	1,108
Operating lease right-of-use assets	8,092	8,470
Other assets	2,144	1,818
Noncurrent assets of discontinued operation	0	21,336
Total assets	260,959	266,487
Current liabilities
Accounts payable	3,314	3,377
Accrued and other current liabilities	17,033	31,988
Deferred revenue	5,523	7,098
Related party payables, net	4,552	4,120
Notes payable	0	238
Current liabilities of discontinued operation	0	10,680
Total current liabilities	30,422	57,501
Deferred revenue, net of current	1,148	1,129
Related party liabilities	25,931	24,227
Related party promissory note	112,666	112,666
Related party convertible note, net	8,994	8,864
Convertible notes, net	86,060	84,648
Deferred income taxes, net	1,654	1,669
Operating lease liabilities	9,264	9,728
Other liabilities	18,411	21,542
Noncurrent liabilities of discontinued operation	0	1,649
Total liabilities	294,550	323,623
Commitments and Contingencies (Note 14)
Stockholders' deficit
Common stock, $0.0001 par value per share, 750,000,000 shares authorized; 110,619,678 and 110,619,678 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively	11	11
Additional paid-in capital	890,623	889,955
Accumulated deficit	(923,819)	(946,884)
Accumulated other comprehensive loss	(406)	(218)
Total stockholders' deficit	(33,591)	(57,136)
Total liabilities and stockholders' deficit	$ 260,959	$ 266,487

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value (usd per share)	$ 0.0001	$ 0.0001
Common stock authorized (shares)	750,000,000	750,000,000
Common stock issued (shares)	110,619,678	110,619,678
Common stock outstanding (shares)	110,619,678	110,619,678

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2020	Mar. 31, 2019
Revenue
Revenue		$ 18,180	$ 20,209
Cost of Revenue:
Total cost of revenue		7,196	10,261
Gross Profit		10,984	9,948
Operating Expenses
Selling, general and administrative		12,427	15,324
Research and development		3,550	3,850
Amortization of acquisition-related assets		867	1,054
Total operating expenses		16,844	20,228
Loss from operations		(5,860)	(10,280)
Interest expense, net		(4,657)	(4,414)
Other income (expense), net		3,454	(2,505)
Loss from related party equity method investment	[1]	(1,784)	(2,210)
Loss from continuing operations before income taxes		(8,847)	(19,409)
Provision for income taxes		93	226
Net loss from continuing operations		(8,940)	(19,635)
Income (loss) from discontinued operations, net of tax		32,005	(288)
Net income (loss)	[1]	$ 23,065	$ (19,923)
Basic and diluted net income (loss) per share
Continuing operations - common stock (in usd per share)		$ (0.08)	$ (0.18)
Discontinued operations - common stock (in usd per share)		0.29	0
Total net income (loss) per share - common stock (in usd per share)		$ 0.21	$ (0.18)
Weighted average shares outstanding
Basic and diluted - common stock (shares)		110,619,780	109,904,336
Total software-related revenue
Revenue
Revenue		$ 18,121	$ 17,802
Cost of Revenue:
Total cost of revenue		6,844	7,011
Software-as-a-service related
Revenue
Revenue		18,121	17,802
Cost of Revenue:
Total cost of revenue		5,701	5,708
Maintenance
Cost of Revenue:
Total cost of revenue		0	70
Amortization of developed technologies
Cost of Revenue:
Total cost of revenue		1,143	1,233
Sequencing and molecular analysis
Revenue
Revenue		59	814
Cost of Revenue:
Total cost of revenue		352	2,427
Home health care services
Revenue
Revenue		0	1,593
Cost of Revenue:
Total cost of revenue		$ 0	$ 823
[1]	The statements for the three months ended March 31, 2020 and 2019 include the Connected Care Business (see Note 4).

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2020	Mar. 31, 2019
Statement of Comprehensive Income [Abstract]
Net income (loss)	[1]	$ 23,065	$ (19,923)
Other comprehensive (loss) income from foreign currency translation		(188)	55
Total other comprehensive (loss) income		(188)	55
Comprehensive income (loss)		$ 22,877	$ (19,868)
[1]	The statements for the three months ended March 31, 2020 and 2019 include the Connected Care Business (see Note 4).

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total		Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2018			109,491,277
Beginning balance at Dec. 31, 2018	$ 2,831		$ 11	$ 887,289	$ (884,122)	$ (347)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	707			707
Shares issued in connection with employee stock plans, net of shares withheld for employee taxes (in shares)			430,370
Shares issued in connection with employee stock plans, net of shares withheld for employee taxes	(53)			(53)
Assignment of NantHealth Labs (see Note 20)	20			20
Other comprehensive loss	55					55
Net income (loss)	(19,923)	[1]			(19,923)
Ending balance (in shares) at Mar. 31, 2019			109,921,647
Ending balance at Mar. 31, 2019	(16,363)		$ 11	887,963	(904,045)	(292)
Beginning balance (in shares) at Dec. 31, 2019			110,619,678
Beginning balance at Dec. 31, 2019	(57,136)		$ 11	889,955	(946,884)	(218)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	668			668
Other comprehensive loss	(188)					(188)
Net income (loss)	23,065	[1]			23,065
Ending balance (in shares) at Mar. 31, 2020			110,619,678
Ending balance at Mar. 31, 2020	$ (33,591)		$ 11	$ 890,623	$ (923,819)	$ (406)
[1]	The statements for the three months ended March 31, 2020 and 2019 include the Connected Care Business (see Note 4).

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net income (loss)	[1]	$ 23,065	$ (19,923)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Gain on sale of businesses	[1]	(32,211)	0
Depreciation and amortization	[1]	4,271	5,819
Amortization of debt discounts and deferred financing offering cost	[1]	1,542	1,357
Change in fair value of derivatives liability	[1]	5	0
Change in fair value of Bookings Commitment	[1]	(3,128)	2,494
Stock-based compensation	[1]	653	650
Deferred income taxes, net	[1]	(227)	164
Provision for bad debt expense	[1]	6	10
Loss from related party equity method investment	[1]	1,784	2,210
Changes in operating assets and liabilities:
Accounts receivable, net	[1]	937	(12)
Inventories	[1]	(18)	80
Related party receivables, net	[1]	0	280
Prepaid expenses and other current assets	[1]	15,444	(1,100)
Accounts payable	[1]	(282)	685
Accrued and other current liabilities	[1]	(14,884)	(80)
Deferred revenue	[1]	(1,433)	1,016
Related party payables, net	[1]	1,937	1,727
Change in operating lease right-of-use assets and liabilities	[1]	(95)	(51)
Other operating assets and liabilities	[1]	(109)	(159)
Net cash used in operating activities	[1]	(2,743)	(4,833)
Cash flows from investing activities:
Net proceeds from sale of businesses	[1]	46,401	0
Purchases of property and equipment, including internal-use software	[1]	(935)	(973)
Net cash provided by (used in) investing activities	[1]	45,466	(973)
Cash flows from financing activities:
Repayments of insurance promissory note	[1]	(238)	0
Tax payments related to stock issued, net of stock withheld, for vested equity awards	[1]	0	(58)
Net cash used in financing activities	[1]	(238)	(58)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	[1]	(11)	3
Net increase (decrease) in cash, cash equivalents and restricted cash	[1]	42,474	(5,861)
Cash, cash equivalents and restricted cash, beginning of period	[1],[2]	6,379	19,441
Cash, cash equivalents and restricted cash, end of period	[1],[2]	$ 48,853	$ 13,580
[1]	The statements for the three months ended March 31, 2020 and 2019 include the Connected Care Business (see Note 4).
[2]	Cash and cash equivalents included restricted cash of $1,136 and $1,375 at December 31, 2019 and March 31, 2020, respectively, included in other assets and $1,136 and $1,136 at December 31, 2018 and March 31, 2019, respectively. Restricted cash consists of funds that are contractually restricted as to usage or withdrawal related to the Company's security deposits in the form of standby letters of credit for leased facilities and funds held in an escrow account related to the sale of the Connected Care Business (see Note 4). No amounts have been drawn upon the letters of credit as of March 31, 2020.

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
Statement of Cash Flows [Abstract]
Restricted cash	$ 1,375	$ 1,136	$ 1,136	$ 1,136

Description of Business and Bas

Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	Description of Business and Basis of Presentation Nature of Business Nant Health, LLC was formed on July 7, 2010, as a Delaware limited liability company. On June 1, 2016, Nant Health, LLC converted into a Delaware corporation (the “LLC Conversion”) and changed its name to NantHealth, Inc. (“NantHealth”). NantHealth, together with its subsidiaries (the “Company”), is a healthcare IT company converging science and technology. The Company works to transform clinical delivery with actionable clinical intelligence at the moment of decision, enabling clinical discovery through real-time machine learning systems. The Company markets certain of its solutions as a comprehensive integrated solution that includes its molecular sequencing and analysis services, clinical decision support, and payer engagement solutions. The Company also markets molecular sequencing and analysis services, clinical decision support, and payer engagement solutions on a stand-alone basis. NantHealth is a majority-owned subsidiary of NantWorks, LLC (“NantWorks”), which is a subsidiary of California Capital Equity, LLC (“Cal Cap”). The three companies were founded by and are led by Dr. Patrick Soon-Shiong. On June 7, 2019, the Company sold its home health care services business (see Note 4). On February 3, 2020, the Company sold certain of its assets related to its Connected Care Business (see Note 4). The sales will enable the Company to focus on its core competencies of genomic sequencing, clinical decision support, and payer engagement. As of March 31, 2020 , the Company conducted the majority of its operations in the United States, the United Kingdom, Singapore and Canada. COVID-19 Pandemic In March 2020, the World Health Organization declared the novel coronavirus (COVID-19) a pandemic. In the same month, the President of the United States declared a State of National Emergency due to the COVID-19 outbreak. Many jurisdictions, particularly in North America (including the United States), Europe and Asia, as well as U.S. states in which the Company operates, including California, have adopted or are considering laws, rules, regulations or decrees intended to address the COVID-19 outbreak, including implementing travel restrictions, closing non-essential businesses and/or restricting daily activities. In addition, many communities have limited, and are considering to further limit, social mobility and gathering. To date, there have been no material adverse impact to the Company's business from the COVID-19 pandemic. Given the unprecedented and evolving nature of the pandemic, the future impact of these changes and potential changes on the Company and its contractors, consultants, customers, resellers and partners are unknown at this time. However, in light of the uncertainties regarding economic, business, social, health and geopolitical conditions, the Company’s revenues, earnings, liquidity, and cash flows could be adversely affected, whether on an annual or quarterly basis. Continued impacts of the COVID-19 pandemic could materially adversely affect the Company’s current and long-term accounts receivable collectibility, as its negatively impacted customers from the pandemic may request temporary relief, delay, or not make scheduled payments. In addition, the deployment of the Company’s solutions may represent a large portion of its customers' investments in software technology. Decisions to make such an investment are impacted by the economic environment in which the customers operate. Uncertain global geopolitical, economic and health conditions and the lack of visibility or the lack of financial resources may cause some customers to reduce, postpone or terminate their investments, or to reduce or not renew ongoing paid services, adversely impacting the Company’s revenues or timing of revenue. Health conditions in some geographic areas where the Company’s customers operate could impact the economic situation of those areas. These conditions, including the COVID-19 pandemic, may present risks for health and limit the ability to travel for Company employees, which could further lengthen the Company’s sales cycle and delay revenue and cash flows in the near-term. For information on the CARES Act, refer to Note 15. Basis of Presentation and Principles of Consolidation The accompanying unaudited Consolidated Financial Statements include the accounts of NantHealth and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. These interim Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and, in the opinion of management, include all adjustments, which are normal and recurring in nature, necessary for a fair presentation of the Company's financial position and results of operations. In accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X as issued by the Securities and Exchange Commission ("SEC"), these Consolidated Financial Statements do not include all of the information and disclosures required by GAAP for complete financial statements. These Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements for the fiscal year ended December 31, 2019 . The results of operations of the entities disposed of are included in the unaudited Consolidated Financial Statements up to the date of disposal and, where appropriate, these operations have been reflected as discontinued operations. The accompanying Consolidated Balance Sheet as of December 31, 2019 has been derived from the audited Consolidated Financial Statements at that date. Assets and liabilities of the discontinued operations are presented separately in the asset and liability sections of the prior period balance sheet. Operating results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year. The Company believes its existing cash, cash equivalents, the $47,250 received from sale of the Connected Care Business in February 2020 (see Note 4), and its ability to borrow from affiliated entities will be sufficient to fund operations through at least 12 months following the issuance date of the financial statements. The Company continues to have its Chairman and CEO’s intent and ability to support the Company’s operations with additional funds as required. The Company may also seek to sell additional equity, through one or more follow-on public offerings or in separate financings, or sell additional debt securities, or obtain a credit facility. However, the Company may not be able to secure such financing in a timely manner or on favorable terms. The Company may also consider selling off components of its business. Without additional funds, the Company may choose to delay or reduce its operating or investment expenditures. Further, because of the risk and uncertainties associated with the commercialization of the Company's existing products as well as products in development, the Company may need additional funds to meet its needs sooner than planned. To date, the Company's primary sources of capital have been the private placement of membership interests prior to its IPO, debt financing agreements, including the promissory note with Nant Capital, LLC (“NantCapital”) and its convertible notes, its IPO, and proceeds from the sale of components of its business.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Use of Estimates The preparation of Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported on the Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates. Segment Reporting The chief operating decision maker for the Company is its Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results, or plans for levels or components below the consolidated unit level. Accordingly, management has determined that the Company operates in one reportable segment. Recently Adopted Accounting Pronouncements Effective January 1, 2020, the Company adopted ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Value Measurement (“ASU 2018-13”) , which modifies the disclosure requirements on fair value measurements. The adoption of this guidance has no impact on the Consolidated Financial Statements. Effective January 1, 2020, the Company adopted, on a prospective basis, ASU No. 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract , which aligns the requirement for capitalizing implementation costs incurred by a customer in a cloud clouding arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software and hosting arrangements that include an internal-use software license. The adoption of this guidance did not have a material impact on the Consolidated Financial Statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , to simplify the accounting for income taxes. The new guidance eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. This ASU is effective for the Company's annual and interim periods beginning in January 1, 2021, and early adoption is permitted. The Company early adopted, on a prospective basis, this ASU in the first quarter of 2020. One of the provisions in this ASU is the change from the intraperiod tax allocation exception in ASC 740-20-45-7 to the incremental approach when there is a current period loss from continuing operations. ASU No. 2019-12 removed this exception, which impacted the Company's tax provision for (benefit from) income taxes between continuing operations and discontinued operations. Upcoming Accounting Standard Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments , which changes how companies measure credit losses on most financial instruments measured at amortized cost, such as loans, receivables and held-to-maturity debt securities. Rather than generally recognizing credit losses when it is probable that the loss has been incurred, the revised guidance requires companies to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount of amortized cost that the Company expects to collect over the instrument's contractual life. ASU No. 2016-13 is effective for fiscal periods beginning after December 15, 2022 and must be adopted as a cumulative effect adjustment to retained earnings. Early adoption is permitted. The Company is still evaluating the effects of this ASU. Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not have, nor are believed by management to have, a material impact on the Company's present or future Consolidated Financial Statements.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2020
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Contract Balances The Company records deferred revenue when cash payments are received, or payment is due, in advance of its fulfillment of performance obligations. During the three months ended March 31, 2020 and 2019, there were revenues of $1,828 and $2,244 recognized, respectively, that were included in the deferred revenue balance at the beginning of the period. Assets Recognized from the Costs to Obtain a Contract with a Customer The Company recognizes an asset for the incremental costs to obtain a contract with a customer, where the stated contract term, with expected renewals, is longer than one year. The Company amortizes these assets over the expected period of benefit. These costs are generally employee sales commissions, with amortization of the balance recorded in selling, general and administrative expenses. The value of these assets was $ 1,394 at March 31, 2020 and $ 1,455 at December 31, 2019 . During the three months ended March 31, 2020 and 2019, the Company recorded amortization of $242 and $170 , respectively. Performance Obligations As of March 31, 2020 , the Company has allocated a total transaction price of $6,904 to unfulfilled performance obligations that are expected to be fulfilled within six years . Excluded from this amount are contracts of less than one year and variable consideration that relates to the value of services provided.

Discontinued Operations and Div

Discontinued Operations and Divestitures	3 Months Ended
	Mar. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations and Divestitures	Discontinued Operations and Divestitures Discontinued Operations Sale of Connected Care Business On January 13, 2020, the Company entered into an asset purchase agreement (the “Purchase Agreement”) with Masimo Corporation (“Masimo”), VCCB Holdings, Inc., a wholly owned subsidiary of Masimo (collectively with Masimo, the “Purchaser”), and, solely with respect to certain provisions of the Purchase Agreement, NantWorks, LLC, an affiliate of the Company. Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchaser certain of its assets related to its Connected Care business, including the products known as DCX (formerly DeviceConX), VCX (formerly VitalsConX), HBox and Shuttle Cable (collectively, the “Connected Care Business”). On February 3, 2020, the Company completed the sale of the Connected Care Business for $47,250 of cash consideration in exchange for assets primarily related to the Connected Care Business (as defined under the terms of the Purchase Agreement). The cash consideration is subject to adjustment based upon the final amount of working capital as of the closing date. The sale of the Connected Care Business qualified as a discontinued operation because it comprised operations and cash flows that could be distinguished, operationally and for financial reporting purposes, from the rest of the Company. The disposal of the Connected Care Business, which represented the Company's medical device interoperability solutions, represented a strategic shift in the Company’s operations as the sale enables the Company to focus on genomic sequencing, clinical decision support, and payer engagement. The total gain on sale of the Connected Care Business consisted of the following: Cash received as consideration $ 47,250 Less: Carrying value of net assets sold (14,190 ) Less: Costs to sell (849 ) Gain on sale of the Connected Care Business $ 32,211 The carrying amounts of the major classes of assets and liabilities of the Company's discontinued operation as of December 31, 2019 were as follows: December 31, Accounts receivable, net $ 4,739 Inventories 798 Prepaid expenses and other current assets 790 Current assets of discontinued operation 6,327 Property, plant, and equipment, net 1,110 Goodwill 18,623 Operating lease right-of-use assets 1,603 Total assets of discontinued operation $ 27,663 Accounts payable $ 574 Accrued and other current liabilities 456 Deferred revenue 9,650 Current liabilities of discontinued operation 10,680 Deferred revenue, net of current 157 Deferred income taxes, net 210 Operating lease liabilities $ 1,282 Total liabilities of discontinued operation $ 12,329 The operating results of the Company's discontinued operation are as follows: Three Months Ended 2020 2019 Major classes of line items constituting pretax income (loss) of discontinued operations Net revenue $ 1,165 $ 3,520 Cost of revenue (467 ) (1,029 ) Selling, general and administrative (524 ) (1,465 ) Research and development (592 ) (1,230 ) Other expense, net (5 ) — Pretax loss from discontinued operations related to major classes of pretax income (loss) (423 ) (204 ) Pretax gain on sale of the Connected Care Business 32,211 — Total pretax income (loss) from discontinued operations 31,788 (204 ) Benefit from income taxes (223 ) — Total income (loss) from discontinued operations, net of tax $ 32,011 $ (204 ) The significant operating and investing cash and noncash items of the discontinued operation included on the Consolidated Statements of Cash Flows for the three months ended March 31, 2020 and 2019 were as follows: Three Months Ended 2020 2019 Cash flows from operating activities: Depreciation and amortization $ 10 $ 100 Gain on sale of the Connected Care Business 32,211 — Cash flows from investing activities: Net proceeds from sale of the Connected Care Business 46,401 — Purchases of property and equipment, including internal-use software 76 — Divestitures Sale of Home Health Care Services Business On June 7, 2019, the Company completed the divestiture of its home health care services business in exchange for cash proceeds of $300 , which resulted in a loss on sale of business of $582 . The home health care services business does not qualify as a discontinued operation as its divestiture does not represent a strategic shift that has had a major impact on the Company's operations or financial results.

Accounts Receivable, net

Accounts Receivable, net	3 Months Ended
	Mar. 31, 2020
Receivables [Abstract]
Accounts Receivable, net	Accounts Receivable, net Accounts receivable are included on the Consolidated Balance Sheets, net of the allowance for doubtful accounts. The allowance for doubtful accounts at March 31, 2020 and December 31, 2019 was $101 and $95 , respectively.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets and Accrued and Other Current Liabilities	3 Months Ended
	Mar. 31, 2020
Other Current Assets And Other Current Liabilities [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets and Accrued and Other Current Liabilities Prepaid expenses and other current assets as of March 31, 2020 and December 31, 2019 consisted of the following: March 31, December 31, Prepaid expenses $ 2,468 $ 1,794 Securities litigation insurance receivable 330 16,627 Other current assets 882 920 Prepaid expenses and other current assets $ 3,680 $ 19,341 Accrued and other current liabilities as of March 31, 2020 and December 31, 2019 consisted of the following: March 31, December 31, Payroll and related costs $ 8,750 $ 8,106 Securities litigation expense payable 330 17,127 Operating lease liabilities 1,613 1,617 Other accrued and other current liabilities 6,340 5,138 Accrued and other current liabilities $ 17,033 $ 31,988
Accrued and Other Current Liabilities	Prepaid Expenses and Other Current Assets and Accrued and Other Current Liabilities Prepaid expenses and other current assets as of March 31, 2020 and December 31, 2019 consisted of the following: March 31, December 31, Prepaid expenses $ 2,468 $ 1,794 Securities litigation insurance receivable 330 16,627 Other current assets 882 920 Prepaid expenses and other current assets $ 3,680 $ 19,341 Accrued and other current liabilities as of March 31, 2020 and December 31, 2019 consisted of the following: March 31, December 31, Payroll and related costs $ 8,750 $ 8,106 Securities litigation expense payable 330 17,127 Operating lease liabilities 1,613 1,617 Other accrued and other current liabilities 6,340 5,138 Accrued and other current liabilities $ 17,033 $ 31,988

Property, Plant and Equipment,

Property, Plant and Equipment, net	3 Months Ended
	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, net	Property, Plant and Equipment, net Property, plant and equipment, net as of March 31, 2020 and December 31, 2019 consisted of the following: March 31, December 31, Computer equipment and software $ 12,144 $ 12,144 Furniture and equipment 2,224 2,292 Leasehold and building improvements 7,135 7,160 Construction in progress - PPE 32 — Property, plant, and equipment, excluding internal-use software 21,535 21,596 Less: Accumulated depreciation and amortization (17,375 ) (17,078 ) Property, plant and equipment, excluding internal-use software, net 4,160 4,518 Internal-use software 33,738 33,278 Construction in progress - Internal-use software 3,344 2,973 Less: Accumulated depreciation and amortization, internal-use software (27,487 ) (25,784 ) Internal-use software, net 9,595 10,467 Property, plant, and equipment, net $ 13,755 $ 14,985 Depreciation and amortization expense from continuing operations was $2,008 for the three months ended March 31, 2020 , of which $1,635 related to internal use software costs. Depreciation and amortization expense from continuing operations was $3,264 for the three months ended March 31, 2019 , of which $2,547 related to internal-use software costs. Amounts capitalized to internal-use software for the three months ended March 31, 2020 and 2019 were $1,210 and $912 , respectively.

Intangible Assets, net

Intangible Assets, net	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, net	Intangible Assets, net The Company’s definite-lived intangible assets as of March 31, 2020 and December 31, 2019 consisted of the following: March 31, December 31, Customer relationships $ 52,000 $ 52,000 Developed technologies 32,000 32,000 Trade name 3,000 3,000 87,000 87,000 Less: Accumulated amortization (37,162 ) (35,152 ) Intangible assets, net $ 49,838 $ 51,848 Amortization of definite-lived intangible assets is provided over their estimated useful lives on a straight-line basis or the pattern in which economic benefits are consumed, if reliably determinable. The Company reviews its definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Amortization expense from continuing operations for the three months ended March 31, 2020 and 2019 was $2,010 and $2,287 , respectively. During the three months ended June 30, 2019, the Company identified an indicator of impairment with respect to the NantHealth Labs, Inc. definite-lived intangible assets given the decline in sales and the Company's decision to cease commercial sales of its liquid biopsy test offering to focus on performing a study to measure the clinical utility of the AR-V7 analyte for informing treatment in patients with castration-resistant prostate cancer. Although the Company will continue this study while also pursuing other strategically aligned clinical studies that support its liquid biopsy platform, the Company determined that the assets were not recoverable given the significant amount of costs required to further build evidence of clinical utility while also ceasing commercial sales of the Liquid GPS product. Therefore, the Company fully impaired the intangible assets as of June 30, 2019 and recorded an impairment loss of $3,977 within operating expenses. The estimated future amortization expense over the next five years and thereafter for the intangible assets that exist as of March 31, 2020 is as follows: Amounts Remainder of 2020 $ 6,029 2021 8,038 2022 8,038 2023 3,467 2024 3,467 2025 3,467 Thereafter 17,332 Total future intangible amortization expense $ 49,838

Goodwill

Goodwill	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill Goodwill as of both March 31, 2020 and December 31, 2019 was $97,307 , net of goodwill allocated to the discontinued operation of $18,623 . The goodwill allocated to the discontinued operation was based on the fair value of the Connected Care Business as a percentage of the total fair value of the Connected Care Business and the Company that remains after the sales transaction (see Note 4). Goodwill acquired in a business combination is tested for impairment annually as of October 1, or between annual tests when an impairment indicator exists.

Investments

Investments	3 Months Ended
	Mar. 31, 2020
Equity Method Investments and Joint Ventures [Abstract]
Investments	Investments Equity method investment Investment in NantOmics In 2015, the Company purchased a total of 169,074,539 Series A-2 units of NantOmics, LLC (“NantOmics”), a related party of the Company, for an aggregate purchase price of $250,774 . The Series A-2 units do not have any voting rights and, at the time of purchase, represented approximately 14.28% of NantOmics’ issued and outstanding membership interests. NantOmics is majority owned by NantWorks and delivers molecular diagnostic capabilities with the intent of providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. The Company applies the equity method to account for its investment in NantOmics as the interest in the equity is similar to a partnership interest. Further, the Company has the ability to exert significant influence over the operating and financial policies of the entity since NantWorks controls both NantHealth and NantOmics. The difference between the carrying amount of the investment in NantOmics and the Company’s underlying equity in NantOmics’ net assets relate to both definite and indefinite-lived intangible assets. At the time of the purchase, the Company attributed $28,195 and $14,382 of these differences to NantOmics’ developed technologies and its reseller agreement with the Company, respectively, prior to the application of developed technology intangibles included in NantOmics net assets, and the remaining basis differences were attributed to goodwill. The Company amortizes the basis differences related to the definite-lived intangible assets over the assets’ estimated useful lives and records these amounts as a reduction in the carrying amount of its investment and an increase in its equity method loss. At February 28, 2018, the Company transferred 9,088,362 of the Series A-2 units to NantOmics as consideration for the assignment of NantHealth Labs, Inc. (see Note 19). An additional 564,779 units were transferred by May 31, 2018. This reduced NantHealth's ownership of NantOmics to approximately 13.58% . Pertaining to the Company's share of NantOmics' income or loss and amortization of basis differences, for the three months ended March 31, 2020 and 2019 , the Company recognized losses of $1,784 and $2,210 , respectively. The Company reports its share of NantOmics’ income or loss and the amortization of basis differences using a one quarter lag. The Company used the following summarized financial information for NantOmics for the three months ended December 31, 2019 and 2018, to record its equity method losses for the three months ended March 31, 2020 and 2019 : Three Months Ended 2019 2018 Revenues $ 223 $ 1,746 Gross loss (1,163 ) (520 ) Loss from operations (3,856 ) (6,884 ) Impairment on equity investments — (12,265 ) Net loss (1,360 ) (17,851 ) Net loss attributable to NantOmics (1,329 ) (17,752 )

Convertible Notes

Convertible Notes	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Convertible Notes	Convertible Notes In December 2016, the Company entered into the Purchase Agreement with J.P. Morgan Securities LLC and Jefferies LLC, as representatives of the several initial purchasers named therein (collectively, the “Initial Purchasers”), to issue and sell $90,000 in aggregate principal amount of its 5.50% senior convertible notes due 2021 ("Convertible Notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and to non-U.S. persons pursuant to Regulation S under the Securities Act. In December 2016, the Company entered into a purchase agreement (the “Cambridge Purchase Agreement”) with Cambridge Equities, L.P. (“Cambridge”), an entity affiliated with Dr. Patrick Soon-Shiong, the Company’s Chairman and Chief Executive Officer, to issue and sell $10,000 in aggregate principal amount of the Convertible Notes in a private placement pursuant to an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act. In December 2016, pursuant to the exercise of the overallotment by the Initial Purchasers, the Company issued an additional $7,000 principal amount of the Convertible Notes. The total net proceeds from this offering were approximately $102,714 , comprised of $9,917 from Cambridge and $92,797 from the Initial Purchasers, after deducting the Initial Purchasers’ discount and debt issuance costs of $4,286 in connection with the Convertible Notes offering. On December 21, 2016, the Company entered into an indenture, relating to the issuance of the Convertible Notes (the “Indenture”), by and between the Company and U.S. Bank National Association, as trustee (the “Trustee”). The interest rates are fixed at 5.50% per year, payable semi-annually on June 15 and December 15 of each year, beginning on June 15, 2017. The Convertible Notes will mature on December 15, 2021, unless earlier repurchased by the Company or converted pursuant to their terms. In connection with the offering of the Convertible Notes, on December 15, 2016, the Company entered into a Second Amended and Restated Promissory Note which amended and restated the Amended and Restated Promissory Note, dated May 9, 2016, between the Company and NantCapital, to, among other things, extend the maturity date of the promissory note to June 15, 2022 and to subordinate such promissory note in right of payment to the Convertible Notes (see Note 19). The initial conversion rate of the Convertible Notes is 82.3893 shares of common stock per $1 principal amount of Convertible Notes (which is equivalent to an initial conversion price of approximately $12.14 per share). Prior to the close of business on the business day immediately preceding September 15, 2021, the Convertible Notes will be convertible only under the following circumstances: (1) during any calendar quarter commencing after March 31, 2017 (and only during such calendar quarter), if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding calendar quarter, the last reported sale price of the Company’s common stock on such trading day is greater than or equal to 120% of the conversion price on such trading day; (2) during the five business day period after any five consecutive trading day period in which, for each day of that period, the trading price per $1 principal amount of the Convertible Notes for such trading day was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on such trading day; or (3) upon the occurrence of specified corporate transactions as described in the Indenture agreement. Upon conversion, the Convertible Notes will be settled in cash, shares of the Company’s common stock or any combination thereof at the Company’s option. Upon the occurrence of a fundamental change (as defined in the Indenture), holders may require the Company to purchase all or a portion of the Convertible Notes in principal amounts of $1 or an integral multiple thereof, for cash at a price equal to 100% of the principal amount of the Convertible Notes to be purchased plus any accrued and unpaid interest to, but excluding, the fundamental change purchase date. The conversion rate will be subject to adjustment upon the occurrence of certain specified events. On or after the date that is one year after the last date of original issuance of the Convertible Notes, if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending within the five trading days immediately preceding a conversion date is greater than or equal to 120% of the conversion price on each applicable trading day, the Company will make an interest make-whole payment to a converting holder (other than a conversion in connection with a make-whole fundamental change in which the conversion rate is adjusted) equal to the sum of the present values of the scheduled payments of interest that would have been made on the Convertible Notes to be converted had such Convertible Notes remained outstanding from the conversion date through the earlier of (i) the date that is three years after the conversion date and (ii) the maturity date if the Convertible Notes had not been so converted. The present values of the remaining interest payments will be computed using a discount rate equal to 2.0% . The Company may pay any interest make-whole payment either in cash or in shares of its common stock, at the Company’s election as described in the Indenture. The Company accounts for convertible debt instruments that may be settled in cash upon conversion (including partial cash settlement) by recording the liability and equity components of the convertible debt separately. The liability component is computed based on the fair value of a similar liability that does not include the conversion option. The liability component includes both the value of the embedded interest make-whole derivative and the carrying value of the Convertible Notes. The equity component is computed based on the total debt proceeds less the fair value of the liability component. The equity component is also recorded as debt discount and amortized as interest expense over the expected term of the Convertible Notes. The liability component of the Convertible Notes on the date of issuance was computed as $83,079 , consisting of the value of the embedded interest make-whole derivative of $1,499 and the carrying value of the Convertible Notes of $81,580 . Accordingly, the equity component on the date of issuance was $23,921 . If the debt is considered current at the balance sheet date, the liability component of the convertible notes will be classified as current liabilities and presented in current portion of convertible notes debt and the equity component of the convertible debt will be considered a redeemable security and presented as redeemable equity on the Company's Consolidated Balance Sheet. Offering costs of $4,286 related to the issuance of the Convertible Notes were allocated to the liability and equity components in proportion to the allocation of the proceeds and accounted for as deferred financing offering costs and equity issuance costs, respectively. Approximately $972 of this amount was allocated to equity and the remaining $3,314 was capitalized as deferred financing offering costs. The debt discounts and deferred financing offering costs on the Convertible Notes are being amortized to interest expense over the contractual terms of the Convertible Notes, using the effective interest method at an effective interest rate of 12.82% . As of March 31, 2020 , the remaining life of the Convertible Notes is approximately 21 months . The following table summarizes how the issuance of the Convertible Notes is reflected in the Company's Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019 . Related Party Others Total Balance as of March 31, 2020 Gross proceeds $ 10,000 $ 97,000 $ 107,000 Unamortized debt discounts and deferred financing offering costs (1,006 ) (10,940 ) (11,946 ) Net carrying amount $ 8,994 $ 86,060 $ 95,054 Balance as of December 31, 2019 Gross proceeds $ 10,000 $ 97,000 $ 107,000 Unamortized debt discounts and deferred financing offering costs (1,136 ) (12,352 ) (13,488 ) Net carrying amount $ 8,864 $ 84,648 $ 93,512 The following tables set forth the Company's interest expense recognized in the Company's Consolidated Statements of Operations: Three Months Ended Related Party Others Total Accrued coupon interest expense $ 137 $ 1,334 $ 1,471 Amortization of debt discounts 127 1,238 1,365 Amortization of deferred financing offering costs 3 174 177 Total convertible notes interest expense $ 267 $ 2,746 $ 3,013 Three Months Ended Related Party Others Total Accrued coupon interest expense $ 137 $ 1,334 $ 1,471 Amortization of debt discounts 113 1,087 1,200 Amortization of deferred financing offering costs 3 154 157 Total convertible notes interest expense $ 253 $ 2,575 $ 2,828

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Liabilities measured at fair value on a recurring basis as of March 31, 2020 and December 31, 2019 consisted of the following: March 31, 2020 Total fair value Quoted price in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Liabilities Bookings Commitment $ 18,854 $ — $ — $ 18,854 Interest make-whole derivative 5 — — 5 December 31, 2019 Total fair value Quoted price in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Liabilities Bookings Commitment $ 21,983 $ — $ — $ 21,983 Interest make-whole derivative — — — — The Company’s intangible assets and goodwill are initially measured at fair value and any subsequent adjustment to the initial fair value occurs only if an impairment charge is recognized. Level 3 Inputs Bookings Commitment On August 3, 2017, the Company entered into an asset purchase agreement (the “APA”) with Allscripts Healthcare Solutions, Inc. (“Allscripts”), pursuant to which the Company agreed to sell to Allscripts substantially all of the assets of the Company’s provider/patient engagement solutions business, including the Company’s FusionFX solution and components of its NantOS software connectivity solutions (the “Business”). On August 25, 2017, the Company and Allscripts completed the sale of the Business (the "Disposition") pursuant to the APA. Concurrent with the closing of the Disposition and as contemplated by the APA, (a) the Company and Allscripts modified the amended and restated mutual license and reseller agreement dated June 26, 2015, which was further amended on December 30, 2017, such that, among other things, the Company committed to deliver a minimum of $95,000 of total bookings over a ten -year period (“Bookings Commitment”) from referral transactions and sales of certain Allscripts products; (b) the Company and Allscripts each licensed certain intellectual property to the other party pursuant to a cross license agreement; (c) the Company agreed to provide certain transition services to Allscripts pursuant to a transition services agreement; and (d) the Company licensed certain software and agreed to sell certain hardware to Allscripts pursuant to a software license and supply agreement. In the event of a Bookings Commitment shortfall at the end of the ten -year period, the Company may be obligated to pay 70% of the shortfall, subject to certain credits. The Company will earn 30% commission from Allscripts on each software referral transaction that results in a booking with Allscripts. The Company accounts for the Bookings Commitment at its estimated fair value over the life of the agreement. The Company values the Bookings Commitment using a Monte Carlo Simulation model to calculate average payments due under the Bookings Commitment, based on management's estimate of its performance in securing bookings and resulting annual payments, discounted at the cost of debt based on a yield curve. The cost of debt used for discounting was between 18% and 21% at March 31, 2020 and between 15% and 17% at December 31, 2019 . The change in fair value is recorded within other income (expense), net in the Company's Consolidated Statements of Operations. The fair value of the Bookings Commitment is dependent on management's estimate of the probability of success on individual opportunities and the cost of debt applied in discounting the liability. The higher the probability of success on each opportunity, the lower the fair value of the Bookings Commitment liability. The lower the cost of debt applied, the higher the value of the liability. Management believes the assumptions used on projected financial information is reasonable, but those assumptions require judgment and are forward looking in nature. However, actual results may differ materially from those projections. The fair value of the Bookings Commitment is most sensitive to management's estimate of the discount rate applied to present value the liability. If the discount rate applied was 2% lower at March 31, 2020 , the fair value of the liability would increase by $2,633 . Convertible Note derivative liability In December 2016, the Company issued $107,000 in aggregate principal amount of Convertible Notes due December 15, 2021, of which $10,000 issued to a related party (see Note 11). The Convertible Notes include an interest make-whole feature whereby if a noteholder converts any of the Convertible Notes one year after the last date of original issuance of the Convertible Notes, they are entitled, in addition to the other consideration payable or deliverable in connection with such conversion, to an interest make-whole payment equal to the sum of the present values of the scheduled payments, computed using a discount rate equal to 2.0% , of interest that would have been made on the Convertible Notes to be converted had such Convertible Notes remained outstanding from the conversion date through the earlier of (i) the date that is three years after the conversion date and (ii) the maturity date if the Convertible Notes had not been so converted. The Company may pay any interest make-whole payment either in cash or in shares of its common stock, at the Company’s election as described in the Indenture. The Company has determined that this feature is an embedded derivative and have recognized the fair value of this derivative as a liability in the Company's Consolidated Balance Sheets, with subsequent changes to fair value recorded through earnings at each reporting period in the Company's Consolidated Statements of Operations as change in fair value of derivative liability. The fair value of the derivative liability includes the estimated volatility and risk-free rate. The higher/lower the estimated volatility, the higher/lower the value of the liability. The higher/lower the risk-free interest rate, the higher/lower the value of the liability. The fair market value for level 3 securities may be highly sensitive to the use of unobservable inputs and subjective assumptions. Generally, changes in significant unobservable inputs may result in significantly lower or higher fair value measurements. The following tables set forth a summary of changes in the fair value of Level 3 liabilities for the three months ended March 31, 2020 : December 31, 2019 Additions Change in fair value March 31, 2020 Liabilities Interest make-whole derivative - related party and others $ — $ — $ 5 $ 5 Bookings Commitment 21,983 — (3,129 ) 18,854 $ 21,983 $ — $ (3,124 ) $ 18,859 Fair Value of Convertible Notes held at amortized cost As of March 31, 2020 and December 31, 2019 , the fair value and carrying value of the Company's Convertible Notes were: Fair Value Carrying Value Face Value 5.5% convertible senior notes due December 15, 2021: Balance as of March 31, 2020 Related party $ 8,906 $ 8,994 $ 10,000 Others 86,388 86,060 97,000 $ 95,294 $ 95,054 $ 107,000 Balance as of December 31, 2019 Related party $ 6,727 $ 8,864 $ 10,000 Others 65,257 84,648 97,000 $ 71,984 $ 93,512 $ 107,000 The fair value shown above represents the fair value of the debt instrument, inclusive of both the debt and equity components, but excluding the derivative liability. The carrying value represents only the carrying value of the debt component. The fair value of the Convertible Notes was determined by using unobservable inputs that are supported by minimal non-active market activity and that are significant to determining the fair value of the debt instrument. The fair value is level 3 in the fair value hierarchy.

Leases

Leases	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Leases	Leases The Company has operating leases for corporate offices, data centers, and certain equipment. The Company's leases have lease terms of 1 year to 11 years, some of which include options to extend the leases for up to 5 years, and some of which include options to terminate the leases within 1 year. NantWorks, a related party, subleases one of the Company's data centers on the same terms the Company agreed with the lessor. Options to extend are included in the lease term where the Company is reasonably certain to exercise the options. Variable payments on the Company's leases are expensed as incurred, as they do not depend on an index, or rate. The Company concluded certain leases for data centers had a term of less than 1 year at inception, as arrangements are only renewed following marketplace assessments and negotiations with vendors. The Company's leases do not indicate the rate implicit in the lease. As such, the Company has used its incremental borrowing rate, determined based on market indications of the rate at which the Company could borrow, adjusted for the term, value and payment schedule of individual leases, at the effective date for ASC 842 or at the lease commencement date for leases entered into after January 1, 2019. Lease expense, charged to selling, general and administrative expense, for the three months ended March 31, 2020 and 2019 consisted of: Three Months Ended March 31, Three Months Ended March 31, 2020 2019 Operating lease cost $ 616 598 Short-term lease cost 255 276 Variable cost 78 49 Sublease income (52 ) (52 ) Total lease cost $ 897 871 Other information regarding the Company's leases: Three Months Ended March 31, Three Months Ended March 31, 2020 2019 Operating cash flows for operating leases (679 ) (586 ) Weighted average remaining lease term - operating leases 5.8 years 6.6 years Weighted average discount rate - operating leases 11 % 11 % As of March 31, 2020 and December 31, 2019, the Company had no material capital leases. The remaining lives of its operating leases ranged from one to ten years as of March 31, 2020 . Future minimum lease payments under the Company's operating leases at March 31, 2020 were: Maturity Analysis Amounts Remainder of 2020 $ 2,040 2021 2,570 2022 2,611 2023 2,652 2024 2,509 2025 656 Thereafter 1,679 Total future minimum lease payments 14,717 Less: imputed interest (3,840 ) Total $ 10,877 As reported on the Consolidated Balance Sheet Accrued and other current liabilities $ 1,613 Operating lease liabilities 9,264 $ 10,877

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies The Company's principal commitments consist of obligations under its outstanding debt obligations, noncancelable leases for its office space, data centers and certain equipment and vendor contracts to provide research services, and purchase obligations under license agreements and reseller agreements. Related Party Promissory Note On January 4, 2016, the Company executed a $112,666 demand promissory note in favor of NantCapital to fund the acquisition of NaviNet. On May 9, 2016 and December 15, 2016, the Promissory Note with NantCapital was amended to provide that all outstanding principal and accrued interest is due and payable on June 15, 2022, and not on demand and the Company subordinated the Promissory Note in right of payment to the Convertible Notes (see Note 11). Indenture Obligations Under Convertible Notes On December 21, 2016, the Company entered into the Indenture relating to the issuance of the $107,000 Convertible Notes, by and between the Company and U.S. Bank National Association the Trustee. The interest rates are fixed at 5.50% per year, payable semi-annually on June 15 and December 15 of each year, beginning on June 15, 2017. The Convertible Notes will mature on December 15, 2021, unless earlier repurchased by the Company or converted pursuant to their terms (see Note 11). Purchase Obligations Under License Agreements and Reseller Agreements In September 2016, the Company entered into a Second Amended and Restated Reseller Agreement for genomic and proteomic sequencing services and related bioinformatics and analysis services with NantOmics, with an effective date of June 19, 2015 (see Note 19). Regulatory Matters The Company is subject to regulatory oversight by the U.S. Food and Drug Administration and other regulatory authorities with respect to the development, manufacturing, and sale of some of the solutions. In addition, the Company is subject to the Health Insurance Portability and Accountability Act (“HIPAA”), the Health Information Technology for Economic and Clinical Health Act and related patient confidentiality laws and regulations with respect to patient information. The Company reviews the applicable laws and regulations regarding effects of such laws and regulations on its operations on an on-going basis and modifies operations as appropriate. The Company believes it is in substantial compliance with all applicable laws and regulations. Failure to comply with regulatory requirements could have a significant adverse effect on the Company’s business and operations. Legal Matters The Company is, from time to time, subject to claims and litigation that arise in the ordinary course of its business. The Company intends to defend vigorously any such litigation that may arise under all defenses that would be available to it. Except as discussed below, in the opinion of management, the ultimate outcome of proceedings of which management is aware, even if adverse to the Company, would not have a material adverse effect on the Company’s consolidated financial condition or results of operations. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources and other factors. Securities Litigation In March 2017, a number of putative class action securities complaints were filed in U.S. District Court for the Central District of California, naming as defendants the Company and certain of our current or former executive officers and directors. These complaints have been consolidated with the lead case captioned Deora v. NantHealth, Inc., 2:17-cv-01825. ("Deora") In June 2017, the lead plaintiffs filed an amended consolidated complaint, which generally alleges that defendants violated federal securities laws by making material misrepresentations in NantHealth’s IPO registration statement and in subsequent public statements. In particular, the complaint refers to various third-party articles in alleging that defendants misrepresented NantHealth’s business with the University of Utah, donations to the university by non-profit entities associated with the Company's founder Dr. Patrick Soon-Shiong, and orders for GPS Cancer. The lead plaintiffs seek unspecified damages and other relief on behalf of putative classes of persons who purchased or acquired NantHealth securities in the IPO or on the open market from June 1, 2016 through May 1, 2017. In March 2018, the court largely denied Defendants’ motion to dismiss the consolidated amended complaint. On July 30, 2019, the court certified the case as a class action. On October 23, 2019, the parties notified the court that they had reached a settlement in principle to resolve the action on a classwide basis in the amount of $16,500 , which was included in accrued and other current liabilities on the Consolidated Balance Sheet at December 31, 2019. The court granted preliminary approval of the settlement on January 31, 2020, and a hearing for final approval of the settlement is scheduled for June 15, 2020. The $16,500 settlement was paid into a settlement fund prior to the payment deadline of March 2, 2020. The majority of the settlement amount was funded by the Company’s insurance carriers, and a portion was funded by the Company. The settlement is contingent upon certain matters, including final approval by the court. Also, the parties have the right to terminate the settlement in certain circumstances. In May 2017, a putative class action complaint was filed in California Superior Court, Los Angeles County, asserting claims for violations of the Securities Act based on allegations similar to those in Deora. That case is captioned Bucks County Employees Retirement Fund v. NantHealth, Inc., BC 662330. The parties have agreed to stay the case. The next case management conference is scheduled for July 31, 2020. The Company believes that the claims lack merit and intends to vigorously defend the litigation. In April 2018, two putative shareholder derivative actions-captioned Engleman v. Soon-Shiong, Case No. 2018-0282-AGB, and Petersen v. Soon-Shiong, Case No. 2018-0302-AGB were filed in the Delaware Court of Chancery. The plaintiff in the Engleman action previously filed a similar complaint in California Superior Court, Los Angeles County, which was dismissed based on a provision in the Company’s charter requiring derivative actions to be brought in Delaware. The Engleman and Petersen complaints contain allegations similar to those in Deora but assert causes of action on behalf of NantHealth against various of the Company’s current or former executive officers and directors for alleged breaches of fiduciary duty, abuse of control, gross mismanagement, and unjust enrichment. The Company is named solely as a nominal defendant. In July 2018, the court issued an order consolidating the Engleman and Petersen actions as in re NantHealth, Inc. Stockholder Litigation, Lead C.A. No. 2018-0302-AGB, appointing Petersen as lead plaintiff, and designating the Petersen complaint as the operative complaint. On September 20, 2018, the defendants moved to dismiss the complaint. In October 2018, in response to the motion to dismiss, Petersen filed an amended complaint. In November 2018, the defendants moved to dismiss the amended complaint. A hearing on the defendants’ motion was held on September 25, 2019. On January 14, 2020, the court issued an order granting in part and denying in part the defendants’ motion to dismiss. The court dismissed all claims except one claim against Dr. Patrick Soon-Shiong for breach of fiduciary duty. Dr. Soon-Shiong and the Company filed answers to the amended complaint on March 30, 2020. In April 2018, a putative shareholder derivative action captioned Shen v. Soon-Shiong was filed in U.S. District Court for the District of Delaware. The complaint contains allegations similar to those in Deora but asserts causes of action on behalf of NantHealth against various of the Company’s current or former executive officers and directors for alleged breaches of fiduciary duty and unjust enrichment, as well as alleged violations of the federal securities laws based on alleged misstatements or omissions in the Company’s 2017 proxy statement. The parties agreed to stay the case pending a decision on defendants’ motion to dismiss in the derivative action in the Delaware Court of Chancery. The stay has been lifted due to the court’s January 14, 2020 decision granting in part and denying in part the motion to dismiss. Real Estate Litigation On March 9, 2018, PayPal, Inc. (“PayPal”) commenced an action against the Company in the Superior Court Department of the Trial Court of the Commonwealth of Massachusetts, for Suffolk County. The action was originally captioned PayPal, Inc. v. NantHealth, Inc., Civil Action No. 18-0780-E. On April 10, 2018, the Superior Court transferred the case to its Business Litigation Section, where it is currently pending and captioned as PayPal, Inc. v. NantHealth, Inc., Civil Action No. 18-0780-BLS1. This action arises out of a Sublease Agreement that PayPal and the Company entered into on or about November 30, 2017. The Sublease Agreement pertained to commercial real estate that PayPal leased at One International Place in Boston, Massachusetts. On January 25, 2018, the Company notified PayPal that we were electing to terminate the Sublease Agreement. In its Verified Complaint, and a contemporaneous notice of default that the Company disputed, PayPal alleges that the Company breached the Sublease Agreement. In addition, PayPal asserts claims for breach of the covenant of good faith and fair dealing, and violations of Massachusetts General Laws, Chapter 93A, sections 2 and 11, and seeks a declaratory judgment recognizing and enforcing the terms of the Sublease Agreement. Among other relief, PayPal seeks damages, treble damages, interest, costs, and attorneys’ fees. On April 12, 2018, the Company filed its answer and jury demand in the action, denying liability. On August 2, 2018, PayPal requested a status conference with the court in order to discuss PayPal’s potential filing of a motion for partial judgment on the pleadings pursuant to Mass. R. Civ. P. 12(c). A Rule 16 Litigation Control Conference (“Rule 16 Conference”) was held on August 22, 2018. During the Rule 16 Conference, the court denied PayPal’s request for leave to file a motion for partial judgment on the pleadings. Following the Rule 16 Conference, the court issued a tracking order setting deadlines and other procedures that would apply to this action. On September 26, 2018, the Company filed its Assented to Motion for Leave to Amend Its Answer. The court granted the Company's motion on October 3, 2018. On October 9, 2018, the Company filed and served its amended answer and jury demand. On January 8, 2019, the parties filed a joint motion to extend certain of the tracking order deadlines, which motion the court granted by endorsed order dated January 9, 2019. On April 4, 2019, PayPal filed a motion to add NantWorks, LLC as a defendant in the litigation, which motion was filed together with PayPal’s supporting memorandum, the Company’s opposition to that motion and PayPal’s reply. In its memorandum supporting that motion, PayPal stated that “PayPal’s damages are in excess of $3 M,” without further explanation as to its damages calculations. The court denied PayPal's motion on April 16, 2019. PayPal served a motion for summary judgment on June 5, 2019. In that motion, PayPal asserted that its actual damages are in excess of $2,300 , which it suggested the court should treble pursuant to the provisions of Massachusetts General Laws, Chapter 93A. The Company served its opposition on July 12, 2019. PayPal responded with a reply to the Company’s opposition on July 18, 2019 and the fully briefed motion for summary judgment was filed that same day. The parties completed fact discovery on May 10, 2019 and completed expert discovery on August 22, 2019. A hearing on PayPal’s motion for summary judgment was held on October 17, 2019. At the hearing, the court indicated its intention to issue a written decision (1) granting PayPal’s motion for summary judgment regarding its claim for breach of the Sublease Agreement, as to liability only and not as to damages; (2) denying PayPal’s motion for summary judgment regarding its claim for unfair and deceptive trade practices in violation of Massachusetts General Laws, Chapter 93A, sections 2 and 11; and (3) finding PayPal’s claim for breach of the covenant of good faith and fair dealing to be irrelevant or moot and denying its motion for summary judgment as to that claim. At the October 17, 2019 hearing, PayPal orally withdrew its claim for attorneys’ fees on its breach of the Sublease Agreement claim only and left uncertain whether it intends to pursue its claim for a declaratory judgment. On December 6, 2019, PayPal served a motion seeking a preliminary injunction that would enjoin and restrain the Company, its officers, agents, attorneys and employees from transferring, conveying, or encumbering, or in any way attempting to pass out of their control any of the Company’s assets or property other than in the ordinary course of business, including but not limited to cash, bonuses, and dividends. In the papers submitted in support of that motion, PayPal asserted that it has a strong likelihood of success in seeking to recover over $2,900 on its claim for breach of the Sublease Agreement, inclusive of pre-judgment interest at the statutory rate. On January 3, 2020, the Company served its opposition to PayPal’s motion for preliminary injunction. On January 9, 2020, PayPal served its reply in support of its motion for preliminary injunction and filed all motion papers with the court. On January 23, 2020, the court issued its written Decision and Order regarding PayPal’s motion for summary judgment. In the Decision and Order, which was docketed on January 27, 2020, the court (1) granted PayPal’s motion for summary judgment regarding its claim for breach of the Sublease Agreement, as to liability only and not as to damages; (2) denied PayPal’s motion for summary judgment regarding its claim for unfair and deceptive trade practices in violation of Massachusetts General Laws, Chapter 93A, sections 2 and 11; (3) denied PayPal’s motion for summary judgment regarding its claim for breach of the covenant of good faith and fair dealing, finding there was no need or basis to impose any additional liability on the Company for conduct that does not give rise to a cause of action independent of the underlying breach of contract claim; and (4) denied PayPal’s motion for summary judgment regarding its request for a declaratory judgment because it added little or nothing of substance to the relief PayPal is entitled to obtain, if at all. Based on the court’s January 23, 2020 Decision and Order, the issue of damages on PayPal’s claim for breach of the Sublease Agreement remains to be determined. The Company has asserted, among other things, that PayPal failed to mitigate any damages that PayPal claims the Company owes. PayPal’s claim for unfair and deceptive practices in violation of Massachusetts General Laws, Chapter 93A, sections 2 and 11, and its requests for treble damages and attorneys’ fees on that claim, as well as its requests for interest and costs on the breach of the Sublease Agreement and Chapter 93A claims, also remain to be determined. A hearing on PayPal’s motion for preliminary injunction was held on January 30, 2020. At the hearing, the court took the motion for preliminary injunction under advisement and scheduled the following: (1) a status conference on September 9, 2020; (2) a final trial conference on January 6, 2021; and (3) a jury trial start date on January 12, 2021. On February 24, 2020, the Company filed a Petition for Interlocutory Relief. The petition sought relief from the Decision and Order granting PayPal’s motion for summary judgment regarding its claim for breach of the Sublease Agreement as to liability only. On March 2, 2020, a single justice of the Massachusetts Appeals Court denied the Company’s Petition for Interlocutory Relief. Starting in late January 2020, PayPal and its attorneys and brokers began producing additional documents that had not been produced during the fact discovery period. These supplemental productions continued through April 2020 and may be ongoing. The Company denies any liability to PayPal and intends to continue vigorously defending the action. Insurance Recoveries The Company has reflected its right to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with the Company’s third-party insurers and receipt is deemed probable. This includes instances where the Company’s third-party insurers have agreed to pay, on the Company’s behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund. The amount of such receivable related to the securities litigation recorded at March 31, 2020 and 2019 was $330 and $16,627 , respectively, and is included in prepaid expenses and other current assets on the Consolidated Balance Sheets .

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The provision for income taxes for the three months ended March 31, 2020 and 2019 from continuing operations was $93 and $226 , respectively. The tax provision for income taxes for the three months ended March 31, 2020 and 2019 from continuing operations included an income tax provision for the consolidated group based on an estimated annual effective tax rate. The effective tax rates for the three months ended March 31, 2020 and 2019 were a provision from continuing operations of 1.05% and 1.16% , respectively. The effective tax rates for the three months ended March 31, 2020 and 2019 differed from the U.S. federal statutory rates of 21% primarily as a result of a reduction to the deferred tax liability related to an indefinite-lived intangible asset, an increase of purchase accounting deferred tax liabilities that cannot be absorbed by the deferred tax assets, nondeductible expenses, state income taxes, foreign income tax rate differential and the impact of valuation allowance on the Company's deferred tax assets. The Company has evaluated all available evidence supporting the realization of its deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that its net deferred tax assets will not be realized in the U.S. Due to uncertainties surrounding the realization of the deferred tax assets, the Company maintains a full valuation allowance against substantially all deferred tax assets. If/when the Company determines that it will be able to realize some portion or all of its deferred tax assets, an adjustment to its valuation allowance on its deferred tax assets would have the effect of increasing net income in the period(s) such determination is made. The Company files income tax returns in the U.S. Federal jurisdiction, various U.S. state jurisdictions and certain foreign jurisdictions. The Company has recently completed an IRS audit for the tax year 2016 with no adjustments. The Company is no longer subject to income tax examination by the U.S. federal, state or local tax authorities for years ended December 31, 2014 or prior, however, its tax attributes, such as net operating loss (“NOL”) carryforwards and tax credits, are still subject to examination in the year they are used. On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act). The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions which are expected to impact the Company's financial statements include removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. Consistent with prior years, the Company expects to continue to generate net losses for the foreseeable future. The Company currently has significant federal and state deferred tax assets attributed to prior net operating losses and research and experimentation tax credits. These deferred tax assets are fully reserved. As the Company has never generated taxable income, the CARES Act feature allowing NOLs originating in 2018, 2019 or 2020 to be carried back five years is not expected to have a significant impact. Management does not expect any other provisions of the CARES Act to have a material impact in 2020.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Amended Certificate of Incorporation In accordance with the Company’s amended and restated certificate of incorporation, which was filed immediately following the closing of its IPO, the Company is authorized to issue 750,000,000 shares of common stock, with a par value of $0.0001 per share, and 20,000,000 shares of undesignated preferred stock, with a par value of $0.0001 per share. Holders of the Company’s common stock are entitled to one vote for each share held on all matters submitted to a vote of its stockholders. Holders of the Company’s common stock have no cumulative voting rights. Further, as of March 31, 2020 and December 31, 2019 , holders of the Company’s common stock have no preemptive, conversion, redemption or subscription rights and there are no sinking fund provisions applicable to the Company’s common stock. Upon liquidation, dissolution or winding-up of the Company, holders of the Company’s common stock are entitled to share ratably in all assets remaining after payment of all liabilities and the liquidation preferences of any outstanding shares of preferred stock. Subject to preferences that may be applicable to any outstanding shares of preferred stock, holders of the Company’s common stock are entitled to receive dividends, if any, as may be declared from time to time by the Company’s board of directors. As of March 31, 2020 , and December 31, 2019 , there were no outstanding shares of preferred stock.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The following table reflects the components of stock-based compensation expense recognized in the Company's Consolidated Statements of Operations: Three Months Ended March 31, 2020 2019 Phantom units: Cost of revenue $ 16 $ 19 Selling, general and administrative 9 16 Research and development 17 (15 ) Total phantom units stock-based compensation expense 42 20 Stock options: Cost of revenue 15 — Selling, general and administrative 237 — Research and development 24 — Total stock options stock-based compensation expense 276 — Restricted stock units: Cost of revenue 7 3 Selling, general and administrative 389 592 Research and development 18 10 Total restricted stock units stock-based compensation expense 414 605 Discontinued operations (79 ) 25 Total stock-based compensation expense 653 650 Amount capitalized to internal-use software 19 57 Total stock-based compensation cost $ 672 $ 707 Phantom Unit Plan The following table summarizes the activity related to the unvested phantom units during the three months ended March 31, 2020 : Number of Units Weighted- Average Grant Date Value Per Phantom Unit Unvested phantom units outstanding - December 31, 2019 120,562 $ 11.49 Forfeited (5,454 ) $ 14.24 Unvested phantom units outstanding - March 31, 2020 115,108 $ 11.38 As of March 31, 2020 , the Company had $46 of unrecognized stock-based compensation expense related to phantom units which will be recognized over a weighted-average period of 0.2 years . 2016 Equity Incentive Plan Stock Options The following table summarizes the activity related to stock options during the three months ended March 31, 2020 : Number of Shares Weighted-Average Exercise Price Stock options outstanding - December 31, 2019 5,815,724 $ 0.56 Forfeited (270,000 ) $ 0.55 Stock options outstanding - March 31, 2020 5,545,724 $ 0.56 Stock options exercisable - March 31, 2020 137,500 $ 0.55 As of March 31, 2020 , the Company had $1,270 of unrecognized stock-based compensation expense related to the stock options. This cost is expected to be recognized over a weighted-average period of 2.3 years . Restricted Stock Units The following table summarizes the activity related to the unvested restricted stock units during the three months ended March 31, 2020 : Number of Units Weighted-Average Grant Date Fair Value Unvested restricted stock units outstanding - December 31, 2019 705,415 $ 2.68 Granted 179,558 $ 1.81 Forfeited (10,954 ) $ 3.39 Unvested restricted stock units outstanding - March 31, 2020 874,019 $ 2.49 Unrecognized compensation expense related to unvested restricted stock units was $610 at March 31, 2020 , which is expected to be recognized as expense over the weighted-average period of 0.6 years .

Net Income (Loss) Per Share

Net Income (Loss) Per Share	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	Net Income (Loss) Per Share Basic and diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the respective periods, without consideration of common stock equivalents. If there is a net loss from continuing operations, diluted net income (loss) per share is computed in the same manner as basic net income (loss) per share is computed, even if the Company reports net income as a result of discontinued operations. The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted net loss per share of common stock for the three months ended March 31, 2020 and 2019 : Three Months Ended 2020 2019 Common Stock Common Stock Net income (loss) per share numerator: Net loss from continuing operations $ (8,940 ) $ (19,635 ) Net income (loss) from discontinued operations 32,005 (288 ) Net income (loss) for basic and diluted net income (loss) per share $ 23,065 $ (19,923 ) Weighted-average shares for basic net income (loss) per share 110,619,780 109,904,336 Effect of dilutive securities — — Weighted-average shares for dilutive net income (loss) per share 110,619,780 109,904,336 Basic and diluted net income (loss) per share Continuing operations - common stock $ (0.08 ) $ (0.18 ) Discontinued operations - common stock $ 0.29 $ — Total net income (loss) per share - common stock $ 0.21 $ (0.18 ) The following number of potential common shares at the end of each period were excluded from the calculation of diluted net loss per share attributable to common stockholders because their effect would have been anti-dilutive for the periods presented: March 31, 2020 2019 Unvested restricted stock — 1 Unvested phantom units 115,108 283,862 Unvested restricted stock units 874,019 1,790,182 Unexercised stock options 5,545,724 — Convertible notes 8,815,655 8,815,655

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions NantWorks Shared Services Agreement In October 2012, the Company entered into a shared services agreement with NantWorks that provides for ongoing services from NantWorks in areas such as public relations, information technology and cloud services, human resources and administration management, finance and risk management, environmental health and safety, sales and marketing services, facilities, procurement and travel, and corporate development and strategy (the "Shared Services Agreement"). The Company is billed quarterly for such services at cost, without mark-up or profit for NantWorks, but including reasonable allocations of employee benefits, facilities and other direct or fairly allocated indirect costs that relate to the associates providing the services. NantHealth also bills NantWorks and affiliates for services such as information technology and cloud services, finance and risk management, and facilities management, on the same basis. During the three months ended March 31, 2020 , the Company incurred $486 of expenses recognized in selling, general and administrative expenses for services provided to the Company by NantWorks and affiliates, net of services provided to NantWorks and affiliates. During the three months ended March 31, 2019 , the Company incurred $574 of expenses recognized in selling, general and administrative expenses for services provided to the Company by NantWorks and affiliates, net of services provided to NantWorks and affiliates. Related Party Receivables and Payables As of both March 31, 2020 and December 31, 2019 , the Company had related party receivables, net of related party payables of $1,931 , primarily consisting of a receivable from Ziosoft KK of $1,658 , which was related to the sale of Qi Imaging. As of March 31, 2020 and December 31, 2019 , the Company had related party payables, net of related party receivables, and related party liabilities of $30,483 and $28,347 , respectively, which primarily relate to amounts owed to NantWorks pursuant to the Shared Services Agreement, amounts owed to NantOmics under the Second Amended Reseller Agreement (defined below), and interest payable. The balance of the related party receivables and payables represent amounts paid by affiliates on behalf of the Company or vice versa. Amended Reseller Agreement On June 19, 2015, the Company entered into a five and a half year exclusive Reseller Agreement with NantOmics for sequencing and bioinformatics services (the "Original Reseller Agreement"). NantOmics is a majority owned subsidiary of NantWorks and is controlled by the Company's Chairman and CEO. On May 9, 2016, the Company and NantOmics executed an Amended and Restated Reseller Agreement (the “Amended Reseller Agreement”), pursuant to which the Company received the worldwide, exclusive right to resell NantOmics’ quantitative proteomic analysis services, as well as related consulting and other professional services, to institutional customers (including insurers and self-insured healthcare providers) throughout the world. The Company retained its existing rights to resell NantOmics’ genomic sequencing and bioinformatics services. Under the Amended Reseller Agreement, the Company is responsible for various aspects of delivering its sequencing and molecular analysis solutions, including patient engagement and communications with providers such as providing interpretations of the reports delivered to the physicians and resolving any disputes, ensuring customer satisfaction, and managing billing and collections. On September 20, 2016, the Company and NantOmics further amended the Reseller Agreement (the "Second Amended Reseller Agreement"). The Second Amended Reseller Agreement permits the Company to use vendors other than NantOmics to provide any or all of the services that are currently being provided by NantOmics and clarifies that the Company is responsible for order fulfillment and branding. The Second Amended Reseller Agreement grants to the Company the right to renew the agreement (with exclusivity) for up to three renewal terms, each lasting three years , if the Company achieves projected volume thresholds, as follows: (i) the first renewal option can be exercised if the Company completes at least 300,000 tests between June 19, 2015 and June 30, 2020; (ii) the second renewal option can be exercised if the Company completes at least 570,000 tests between July 1, 2020 and June 30, 2023; and (iii) the third renewal option can be exercised if the Company completes at least 760,000 tests between July 1, 2023 and June 30, 2026. If the Company does not meet the applicable volume threshold during the initial term or the first or second exclusive renewal terms, the Company can renew for a single additional three year term, but only on a non-exclusive basis. The Company agreed to pay NantOmics noncancelable annual minimum fees of $2,000 per year for each of the calendar years from 2016 through 2020 and, subject to the Company exercising at least one of its renewal options described above, the Company is required to pay annual minimum fees to NantOmics of at least $25,000 per year for each of the calendar years from 2021 through 2023 and $50,000 per year for each of the calendar years from 2024 through 2029. On December 18, 2017, the Company and NantOmics executed Amendment No. 1 to the Second Amended Reseller Agreement. The Second Amended Reseller Agreement was amended to allow fee adjustments with respect to services completed by NantOmics between the amendment effective date of October 1, 2017 to June 30, 2018. On April 23, 2019, the Company and NantOmics executed Amendment No. 2 to the Second Amended Reseller Agreement. The Second Amended Reseller Agreement was amended to set a fixed fee with respect to services completed by NantOmics between the amendment effective date and the end of the Initial Term, December 31, 2020. As of March 31, 2020 and December 31, 2019 , the Company had $108 and $197 , respectively, of outstanding related party payables under the Second Amended Reseller Agreement. During the three months ended March 31, 2020 , direct costs of $36 were recorded as cost of revenue related to the Second Amended Reseller Agreement. During the three months ended March 31, 2019 , direct costs of $1,068 were recorded as cost of revenue related to the Second Amended Reseller Agreement. Cambridge Purchase Agreement On December 15, 2016, the Company entered into the Cambridge Purchase Agreement with Cambridge (“Cambridge”), an entity affiliated with the Company's Chairman and CEO, Dr. Patrick Soon-Shiong, to issue and sell $10,000 in aggregate principal amount of the Convertible Notes in a private placement pursuant to an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act. The Cambridge Purchase Agreement includes customary representations, warranties and covenants by the Company and customary closing conditions (see Note 11). The accrued and unpaid interest on the Convertible Notes held by Cambridge was $162 and $24 at March 31, 2020 and December 31, 2019 , respectively, as part of current related party payables, net on the Consolidated Balance Sheets. Liquid Tumor Profiling Services Agreements In March 2018, NantHealth Labs, a wholly-owned subsidiary of the Company, and NantKwest, Inc. ("NantKwest"), an affiliate, entered into agreements whereby NantHealth Labs is providing liquid tumor profiling services to NantKwest for clinical trials, on an annual, stand-ready, basis from the date of the first test of each participant, with revenues recognized ratably over time for the period of the stand-ready obligation. In June 2018, NantHealth Labs entered into similar agreements to provide liquid tumor profiling services to Altor BioScience ("Altor"), ImmunityBio, Inc. ("ImmunityBio", formerly NantCell, Inc.), and NantBioScience, Inc. ("NantBio"), all affiliates of the Company. During the three months ended March 31, 2020 , the Company did no t record any revenue under these agreements. During the three months ended March 31, 2019 , the Company recorded revenues of $349 under these agreements. As of both March 31, 2020 and December 31, 2019 , the Company had $110 of accounts receivable from related parties due to these agreements. Related Party Promissory Notes On January 4, 2016, the Company executed a $112,666 demand promissory note in favor of NantCapital to fund the acquisition of NaviNet. The note bears interest at a per annum rate of 5.0% , compounded annually and computed on the basis of the actual number of days elapsed and a year of 365 or 366 days, as the case may be. The unpaid principal and any accrued and unpaid interest on the note were originally due and payable on demand in either (i) cash, (ii) shares of the Company's common stock based on per share price of $18.6126 , (iii) Series A-2 units of NantOmics based on a per unit price of $1.484 to the extent such equity is owned by the Company or (iv) any combination of the foregoing, all at the option of NantCapital. Subject to the preceding sentence, the Company may prepay the outstanding amount at any time, either in whole or in part, without premium or penalty and without the prior consent of NantCapital. On May 9, 2016, the promissory note with NantCapital was amended to provide that all outstanding principal and accrued interest is due and payable on June 30, 2021, and not on demand. On December 15, 2016, in connection with the offering of the Convertible Notes, the Company entered into a Second Amended and Restated Promissory Note which amends and restates the Amended and Restated Promissory Note, dated May 9, 2016, between the Company and NantCapital, to, among other things, extend the maturity date of the promissory note to June 15, 2022 and to subordinate the promissory note in right of payment to the Convertible Notes (see Note 11). No other terms of the promissory note were changed. As of March 31, 2020 and December 31, 2019 , the total principal and interest outstanding on the promissory note amounted to $138,597 and $136,893 , respectively. The accrued and unpaid interest on the promissory note as of March 31, 2020 and December 31, 2019 was $25,931 and $24,227 , respectively, included as part of noncurrent related party liabilities on the Consolidated Balance Sheets. The Company can request additional advances subject to NantCapital approval. NantCapital has the option, but not the obligation, to require the Company to repay any such amount in cash, Series A-2 units of NantOmics (based on a per unit price of $1.484 ) held by the Company, shares of the Company's common stock based on a per share price of $18.6126 (if such equity exists at the time of repayment), or any combination of the foregoing at the sole discretion of NantCapital. On January 22, 2016, the Company executed a demand promissory note in favor of NantOmics. The principal amount of the initial advance totaled $20,000 . On March 8, 2016, NantOmics made a second advance to the Company for $20,000 . The note bears interest at a per annum rate of 5.0% and is compounded annually. In May and June of 2016, the Company executed amendments to the demand promissory note with NantOmics, which provide that all unpaid principal of each advance owed to NantOmics and any accrued and unpaid interest would convert automatically into shares of the Company’s common stock after pricing of the Company’s IPO and immediately after conversion of the Company from a limited liability company to a corporation. On June 1, 2016, approximately $40,590 of principal and accrued interest under the promissory note with NantOmics was converted into 2,899,297 shares of the Company’s common stock in connection with the IPO. The Company can request additional advances subject to NantOmics approval. As of March 31, 2020 , there was no outstanding balance on the promissory note. On August 8, 2018, the Company executed a promissory note in favor of NantCapital, with a maturity date of June 15, 2022. The note bears interest at a per annum rate of 9.75% and is compounded annually, with interest payments on outstanding amounts due on June 15 and December 15 of each calendar year. No advances have currently been made under the note. The note allows the Company to request advances, up to a maximum commitment of $100,000 . Advances can be requested of up to $10,000 per calendar quarter until March 31, 2019 and, following that, up to $20,000 per calendar quarter until December 31, 2020, after which no further advances can be requested. The promissory note is subordinated to the Convertible Notes (see Note 11). The promissory note includes customary negative covenants and a Performance to Plan - Adjusted EBITDA covenant, that stipulates, in order for the Company to draw on the promissory note, the profit measure, as defined in the agreement, may not negatively deviate from board approved financial plans by more than 25% . At March 31, 2020 , the Company was in compliance with the covenants.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited Consolidated Financial Statements include the accounts of NantHealth and its subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. These interim Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and, in the opinion of management, include all adjustments, which are normal and recurring in nature, necessary for a fair presentation of the Company's financial position and results of operations. In accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X as issued by the Securities and Exchange Commission ("SEC"), these Consolidated Financial Statements do not include all of the information and disclosures required by GAAP for complete financial statements. These Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements for the fiscal year ended December 31, 2019 . The results of operations of the entities disposed of are included in the unaudited Consolidated Financial Statements up to the date of disposal and, where appropriate, these operations have been reflected as discontinued operations. The accompanying Consolidated Balance Sheet as of December 31, 2019 has been derived from the audited Consolidated Financial Statements at that date. Assets and liabilities of the discontinued operations are presented separately in the asset and liability sections of the prior period balance sheet. Operating results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year.
Use of Estimates	Use of Estimates The preparation of Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported on the Consolidated Financial Statements and accompanying notes. Actual results may differ from those estimates.
Segment Reporting	Segment Reporting The chief operating decision maker for the Company is its Chief Executive Officer. The Chief Executive Officer reviews financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. The Company has one business activity and there are no segment managers who are held accountable for operations, operating results, or plans for levels or components below the consolidated unit level. Accordingly, management has determined that the Company operates in one reportable segment.
Recently Adopted and Upcoming Accounting Pronouncements	Recently Adopted Accounting Pronouncements Effective January 1, 2020, the Company adopted ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Value Measurement (“ASU 2018-13”) , which modifies the disclosure requirements on fair value measurements. The adoption of this guidance has no impact on the Consolidated Financial Statements. Effective January 1, 2020, the Company adopted, on a prospective basis, ASU No. 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract , which aligns the requirement for capitalizing implementation costs incurred by a customer in a cloud clouding arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software and hosting arrangements that include an internal-use software license. The adoption of this guidance did not have a material impact on the Consolidated Financial Statements. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , to simplify the accounting for income taxes. The new guidance eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. This ASU is effective for the Company's annual and interim periods beginning in January 1, 2021, and early adoption is permitted. The Company early adopted, on a prospective basis, this ASU in the first quarter of 2020. One of the provisions in this ASU is the change from the intraperiod tax allocation exception in ASC 740-20-45-7 to the incremental approach when there is a current period loss from continuing operations. ASU No. 2019-12 removed this exception, which impacted the Company's tax provision for (benefit from) income taxes between continuing operations and discontinued operations. Upcoming Accounting Standard Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments , which changes how companies measure credit losses on most financial instruments measured at amortized cost, such as loans, receivables and held-to-maturity debt securities. Rather than generally recognizing credit losses when it is probable that the loss has been incurred, the revised guidance requires companies to recognize an allowance for credit losses for the difference between the amortized cost basis of a financial instrument and the amount of amortized cost that the Company expects to collect over the instrument's contractual life. ASU No. 2016-13 is effective for fiscal periods beginning after December 15, 2022 and must be adopted as a cumulative effect adjustment to retained earnings. Early adoption is permitted. The Company is still evaluating the effects of this ASU. Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not have, nor are believed by management to have, a material impact on the Company's present or future Consolidated Financial Statements.

Discontinued Operations and D_2

Discontinued Operations and Divestitures Discontinued Operations and Divestitures (Tables)	3 Months Ended
	Mar. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
Schedules of Discontinued Operations	The total gain on sale of the Connected Care Business consisted of the following: Cash received as consideration $ 47,250 Less: Carrying value of net assets sold (14,190 ) Less: Costs to sell (849 ) Gain on sale of the Connected Care Business $ 32,211 The carrying amounts of the major classes of assets and liabilities of the Company's discontinued operation as of December 31, 2019 were as follows: December 31, Accounts receivable, net $ 4,739 Inventories 798 Prepaid expenses and other current assets 790 Current assets of discontinued operation 6,327 Property, plant, and equipment, net 1,110 Goodwill 18,623 Operating lease right-of-use assets 1,603 Total assets of discontinued operation $ 27,663 Accounts payable $ 574 Accrued and other current liabilities 456 Deferred revenue 9,650 Current liabilities of discontinued operation 10,680 Deferred revenue, net of current 157 Deferred income taxes, net 210 Operating lease liabilities $ 1,282 Total liabilities of discontinued operation $ 12,329 The operating results of the Company's discontinued operation are as follows: Three Months Ended 2020 2019 Major classes of line items constituting pretax income (loss) of discontinued operations Net revenue $ 1,165 $ 3,520 Cost of revenue (467 ) (1,029 ) Selling, general and administrative (524 ) (1,465 ) Research and development (592 ) (1,230 ) Other expense, net (5 ) — Pretax loss from discontinued operations related to major classes of pretax income (loss) (423 ) (204 ) Pretax gain on sale of the Connected Care Business 32,211 — Total pretax income (loss) from discontinued operations 31,788 (204 ) Benefit from income taxes (223 ) — Total income (loss) from discontinued operations, net of tax $ 32,011 $ (204 ) The significant operating and investing cash and noncash items of the discontinued operation included on the Consolidated Statements of Cash Flows for the three months ended March 31, 2020 and 2019 were as follows: Three Months Ended 2020 2019 Cash flows from operating activities: Depreciation and amortization $ 10 $ 100 Gain on sale of the Connected Care Business 32,211 — Cash flows from investing activities: Net proceeds from sale of the Connected Care Business 46,401 — Purchases of property and equipment, including internal-use software 76 —

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets and Accrued and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2020
Other Current Assets And Other Current Liabilities [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets as of March 31, 2020 and December 31, 2019 consisted of the following: March 31, December 31, Prepaid expenses $ 2,468 $ 1,794 Securities litigation insurance receivable 330 16,627 Other current assets 882 920 Prepaid expenses and other current assets $ 3,680 $ 19,341
Schedule of Accrued and Other Current Liabilities	Accrued and other current liabilities as of March 31, 2020 and December 31, 2019 consisted of the following: March 31, December 31, Payroll and related costs $ 8,750 $ 8,106 Securities litigation expense payable 330 17,127 Operating lease liabilities 1,613 1,617 Other accrued and other current liabilities 6,340 5,138 Accrued and other current liabilities $ 17,033 $ 31,988

Property, Plant and Equipment_2

Property, Plant and Equipment, net (Tables)	3 Months Ended
	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment, net	Property, plant and equipment, net as of March 31, 2020 and December 31, 2019 consisted of the following: March 31, December 31, Computer equipment and software $ 12,144 $ 12,144 Furniture and equipment 2,224 2,292 Leasehold and building improvements 7,135 7,160 Construction in progress - PPE 32 — Property, plant, and equipment, excluding internal-use software 21,535 21,596 Less: Accumulated depreciation and amortization (17,375 ) (17,078 ) Property, plant and equipment, excluding internal-use software, net 4,160 4,518 Internal-use software 33,738 33,278 Construction in progress - Internal-use software 3,344 2,973 Less: Accumulated depreciation and amortization, internal-use software (27,487 ) (25,784 ) Internal-use software, net 9,595 10,467 Property, plant, and equipment, net $ 13,755 $ 14,985

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	The Company’s definite-lived intangible assets as of March 31, 2020 and December 31, 2019 consisted of the following: March 31, December 31, Customer relationships $ 52,000 $ 52,000 Developed technologies 32,000 32,000 Trade name 3,000 3,000 87,000 87,000 Less: Accumulated amortization (37,162 ) (35,152 ) Intangible assets, net $ 49,838 $ 51,848
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The estimated future amortization expense over the next five years and thereafter for the intangible assets that exist as of March 31, 2020 is as follows: Amounts Remainder of 2020 $ 6,029 2021 8,038 2022 8,038 2023 3,467 2024 3,467 2025 3,467 Thereafter 17,332 Total future intangible amortization expense $ 49,838

Investments (Tables)

Investments (Tables)	3 Months Ended
	Mar. 31, 2020
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments	The Company used the following summarized financial information for NantOmics for the three months ended December 31, 2019 and 2018, to record its equity method losses for the three months ended March 31, 2020 and 2019 : Three Months Ended 2019 2018 Revenues $ 223 $ 1,746 Gross loss (1,163 ) (520 ) Loss from operations (3,856 ) (6,884 ) Impairment on equity investments — (12,265 ) Net loss (1,360 ) (17,851 ) Net loss attributable to NantOmics (1,329 ) (17,752 )

Convertible Notes (Tables)

Convertible Notes (Tables)	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Convertible Debt	The following table summarizes how the issuance of the Convertible Notes is reflected in the Company's Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019 . Related Party Others Total Balance as of March 31, 2020 Gross proceeds $ 10,000 $ 97,000 $ 107,000 Unamortized debt discounts and deferred financing offering costs (1,006 ) (10,940 ) (11,946 ) Net carrying amount $ 8,994 $ 86,060 $ 95,054 Balance as of December 31, 2019 Gross proceeds $ 10,000 $ 97,000 $ 107,000 Unamortized debt discounts and deferred financing offering costs (1,136 ) (12,352 ) (13,488 ) Net carrying amount $ 8,864 $ 84,648 $ 93,512
Schedule of Interest Expense	The following tables set forth the Company's interest expense recognized in the Company's Consolidated Statements of Operations: Three Months Ended Related Party Others Total Accrued coupon interest expense $ 137 $ 1,334 $ 1,471 Amortization of debt discounts 127 1,238 1,365 Amortization of deferred financing offering costs 3 174 177 Total convertible notes interest expense $ 267 $ 2,746 $ 3,013 Three Months Ended Related Party Others Total Accrued coupon interest expense $ 137 $ 1,334 $ 1,471 Amortization of debt discounts 113 1,087 1,200 Amortization of deferred financing offering costs 3 154 157 Total convertible notes interest expense $ 253 $ 2,575 $ 2,828

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	Liabilities measured at fair value on a recurring basis as of March 31, 2020 and December 31, 2019 consisted of the following: March 31, 2020 Total fair value Quoted price in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Liabilities Bookings Commitment $ 18,854 $ — $ — $ 18,854 Interest make-whole derivative 5 — — 5 December 31, 2019 Total fair value Quoted price in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Liabilities Bookings Commitment $ 21,983 $ — $ — $ 21,983 Interest make-whole derivative — — — —
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following tables set forth a summary of changes in the fair value of Level 3 liabilities for the three months ended March 31, 2020 : December 31, 2019 Additions Change in fair value March 31, 2020 Liabilities Interest make-whole derivative - related party and others $ — $ — $ 5 $ 5 Bookings Commitment 21,983 — (3,129 ) 18,854 $ 21,983 $ — $ (3,124 ) $ 18,859 Fair Value of Convertible Notes held at amortized cost As of March 31, 2020 and December 31, 2019 , the fair value and carrying value of the Company's Convertible Notes were: Fair Value Carrying Value Face Value 5.5% convertible senior notes due December 15, 2021: Balance as of March 31, 2020 Related party $ 8,906 $ 8,994 $ 10,000 Others 86,388 86,060 97,000 $ 95,294 $ 95,054 $ 107,000 Balance as of December 31, 2019 Related party $ 6,727 $ 8,864 $ 10,000 Others 65,257 84,648 97,000 $ 71,984 $ 93,512 $ 107,000

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2020
Leases [Abstract]
Lease, Cost	Lease expense, charged to selling, general and administrative expense, for the three months ended March 31, 2020 and 2019 consisted of: Three Months Ended March 31, Three Months Ended March 31, 2020 2019 Operating lease cost $ 616 598 Short-term lease cost 255 276 Variable cost 78 49 Sublease income (52 ) (52 ) Total lease cost $ 897 871 Other information regarding the Company's leases: Three Months Ended March 31, Three Months Ended March 31, 2020 2019 Operating cash flows for operating leases (679 ) (586 ) Weighted average remaining lease term - operating leases 5.8 years 6.6 years Weighted average discount rate - operating leases 11 % 11 %
Operating Lease Maturities	Future minimum lease payments under the Company's operating leases at March 31, 2020 were: Maturity Analysis Amounts Remainder of 2020 $ 2,040 2021 2,570 2022 2,611 2023 2,652 2024 2,509 2025 656 Thereafter 1,679 Total future minimum lease payments 14,717 Less: imputed interest (3,840 ) Total $ 10,877 As reported on the Consolidated Balance Sheet Accrued and other current liabilities $ 1,613 Operating lease liabilities 9,264 $ 10,877

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	The following table reflects the components of stock-based compensation expense recognized in the Company's Consolidated Statements of Operations: Three Months Ended March 31, 2020 2019 Phantom units: Cost of revenue $ 16 $ 19 Selling, general and administrative 9 16 Research and development 17 (15 ) Total phantom units stock-based compensation expense 42 20 Stock options: Cost of revenue 15 — Selling, general and administrative 237 — Research and development 24 — Total stock options stock-based compensation expense 276 — Restricted stock units: Cost of revenue 7 3 Selling, general and administrative 389 592 Research and development 18 10 Total restricted stock units stock-based compensation expense 414 605 Discontinued operations (79 ) 25 Total stock-based compensation expense 653 650 Amount capitalized to internal-use software 19 57 Total stock-based compensation cost $ 672 $ 707
Schedule of Share-based Compensation, Activity	The following table summarizes the activity related to the unvested phantom units during the three months ended March 31, 2020 : Number of Units Weighted- Average Grant Date Value Per Phantom Unit Unvested phantom units outstanding - December 31, 2019 120,562 $ 11.49 Forfeited (5,454 ) $ 14.24 Unvested phantom units outstanding - March 31, 2020 115,108 $ 11.38
Activity related to unvested stock options	The following table summarizes the activity related to stock options during the three months ended March 31, 2020 : Number of Shares Weighted-Average Exercise Price Stock options outstanding - December 31, 2019 5,815,724 $ 0.56 Forfeited (270,000 ) $ 0.55 Stock options outstanding - March 31, 2020 5,545,724 $ 0.56 Stock options exercisable - March 31, 2020 137,500 $ 0.55
Schedule of Nonvested Restricted Stock Units Activity	The following table summarizes the activity related to the unvested restricted stock units during the three months ended March 31, 2020 : Number of Units Weighted-Average Grant Date Fair Value Unvested restricted stock units outstanding - December 31, 2019 705,415 $ 2.68 Granted 179,558 $ 1.81 Forfeited (10,954 ) $ 3.39 Unvested restricted stock units outstanding - March 31, 2020 874,019 $ 2.49

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2020
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted net loss per share of common stock for the three months ended March 31, 2020 and 2019 : Three Months Ended 2020 2019 Common Stock Common Stock Net income (loss) per share numerator: Net loss from continuing operations $ (8,940 ) $ (19,635 ) Net income (loss) from discontinued operations 32,005 (288 ) Net income (loss) for basic and diluted net income (loss) per share $ 23,065 $ (19,923 ) Weighted-average shares for basic net income (loss) per share 110,619,780 109,904,336 Effect of dilutive securities — — Weighted-average shares for dilutive net income (loss) per share 110,619,780 109,904,336 Basic and diluted net income (loss) per share Continuing operations - common stock $ (0.08 ) $ (0.18 ) Discontinued operations - common stock $ 0.29 $ — Total net income (loss) per share - common stock $ 0.21 $ (0.18 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following number of potential common shares at the end of each period were excluded from the calculation of diluted net loss per share attributable to common stockholders because their effect would have been anti-dilutive for the periods presented: March 31, 2020 2019 Unvested restricted stock — 1 Unvested phantom units 115,108 283,862 Unvested restricted stock units 874,019 1,790,182 Unexercised stock options 5,545,724 — Convertible notes 8,815,655 8,815,655

Summary of Significant Accoun_3

Summary of Significant Accounting Policies Narrative (Details)	3 Months Ended
	Mar. 31, 2020business_activitysegment
Accounting Policies [Abstract]
Number of business activities | business_activity	1
Number of reportable segments | segment	1

Revenue Recognition (Details)

Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Revenue recognized	$ 1,828	$ 2,244
Capitalized contract cost	1,394		$ 1,455
Amortization of contract costs	$ 242	$ 170

Revenue Recognition Performance

Revenue Recognition Performance Obligations (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Revenue from Contract with Customer [Abstract]
Unfulfilled performance obligations	$ 6,904
Description of timing of performance obligations	expected to be fulfilled within six years

Discontinued Operations and D_3

Discontinued Operations and Divestitures Narrative (Details) - USD ($) $ in Thousands		Feb. 03, 2020	Jun. 07, 2019	Mar. 31, 2020	Mar. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss on sale of business	[1]			$ (32,211)	$ 0
Connected Care Business | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash received as consideration		$ 47,250
Less: Carrying value of net assets sold		(14,190)
Less: Costs to sell		$ (849)
Gain on sale of the Connected Care Business				$ 32,211	$ 0
Home health care services | Disposal Group, Disposed of by Sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash received as consideration			$ 300
Loss on sale of business			$ 582
[1]	The statements for the three months ended March 31, 2020 and 2019 include the Connected Care Business (see Note 4).

Discontinued Operations and D_4

Discontinued Operations and Divestitures Schedule of Major Classes of Assets and Liabilities of Discontinued Operations (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Current assets of discontinued operation	$ 0	$ 6,327
Goodwill	18,623	18,623
Current liabilities of discontinued operation	$ 0	10,680
Connected Care Business | Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable, net		4,739
Inventories		798
Prepaid expenses and other current assets		790
Current assets of discontinued operation		6,327
Property, plant, and equipment, net		1,110
Goodwill		18,623
Operating lease right-of-use assets		1,603
Total assets of discontinued operation		27,663
Accounts payable		574
Accrued and other current liabilities		456
Deferred revenue		9,650
Current liabilities of discontinued operation		10,680
Deferred revenue, net of current		157
Deferred income taxes, net		210
Operating lease liabilities		1,282
Total liabilities of discontinued operation		$ 12,329

Discontinued Operations and D_5

Discontinued Operations and Divestitures Schedule of Operating Results of Discontinued Operations (Details) - Connected Care Business - Discontinued Operations, Disposed of by Sale - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net revenue	$ 1,165	$ 3,520
Cost of revenue	(467)	(1,029)
Selling, general and administrative	(524)	(1,465)
Research and development	(592)	(1,230)
Other expense, net	(5)	0
Pretax loss from discontinued operations related to major classes of pretax income (loss)	(423)	(204)
Gain on sale of the Connected Care Business	32,211	0
Total pretax income (loss) from discontinued operations	31,788	(204)
Benefit from income taxes	(223)	0
Total income (loss) from discontinued operations, net of tax	$ 32,011	$ (204)

Discontinued Operations and D_6

Discontinued Operations and Divestitures Schedule of Significant Operating and Investing Cash and Noncash Items (Details) - USD ($) $ in Thousands		Feb. 03, 2020	Mar. 31, 2020	Mar. 31, 2019
Cash flows from investing activities:
Net proceeds from sale of the Connected Care Business	[1]		$ 46,401	$ 0
Connected Care Business | Discontinued Operations, Disposed of by Sale
Cash flows from operating activities:
Depreciation and amortization			10	100
Gain on sale of the Connected Care Business			32,211	0
Cash flows from investing activities:
Net proceeds from sale of the Connected Care Business		$ 46,401		0
Purchases of property and equipment, including internal-use software			$ 76	$ 0
[1]	The statements for the three months ended March 31, 2020 and 2019 include the Connected Care Business (see Note 4).

Accounts Receivable, net (Detai

Accounts Receivable, net (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Receivables [Abstract]
Allowance for doubtful accounts	$ 101	$ 95

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets and Accrued and Other Current Liabilities Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Other Current Assets And Other Current Liabilities [Abstract]
Prepaid expenses	$ 2,468	$ 1,794
Securities litigation insurance receivable	330	16,627
Other current assets	882	920
Prepaid expenses and other current assets	$ 3,680	$ 19,341

Prepaid Expenses and Other Cu_4

Prepaid Expenses and Other Current Assets and Accrued and Other Current Liabilities Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Other Current Assets And Other Current Liabilities [Abstract]
Payroll and related costs	$ 8,750	$ 8,106
Securities litigation expense payable	330	17,127
Operating lease liabilities	1,613	1,617
Other accrued and other current liabilities	6,340	5,138
Accrued and other current liabilities	$ 17,033	$ 31,988

Property, Plant and Equipment_3

Property, Plant and Equipment, net Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property, plant, and equipment, net	$ 13,755		$ 14,985
Depreciation expense	2,008	$ 3,264
Amount capitalized to internal use software	1,210	912
Property, plant, and equipment, excluding internal-use software
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	21,535		21,596
Less: Accumulated depreciation and amortization	(17,375)		(17,078)
Property, plant, and equipment, net	4,160		4,518
Computer equipment and software
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	12,144		12,144
Furniture and equipment
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	2,224		2,292
Leasehold and building improvements
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	7,135		7,160
Construction in progress - PPE
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	32		0
Internal-use software
Property, Plant and Equipment [Line Items]
Property, plant, and equipment	33,738		33,278
Construction in progress - Internal-use software	3,344		2,973
Less: Accumulated depreciation and amortization	(27,487)		(25,784)
Property, plant, and equipment, net	9,595		$ 10,467
Depreciation expense	$ 1,635	$ 2,547

Intangible Assets, net Schedule

Intangible Assets, net Schedule of Definite-Lived Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 87,000	$ 87,000
Less: Accumulated amortization	(37,162)	(35,152)
Intangible assets, net	49,838	51,848
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	52,000	52,000
Developed technologies
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	32,000	32,000
Trade name
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 3,000	$ 3,000

Intangible Assets, net Narrativ

Intangible Assets, net Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 2,010		$ 2,287
Impairment of intangible assets		$ 3,977

Intangible Assets, net Schedu_2

Intangible Assets, net Schedule of Future Amortization of Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Remainder of 2020	$ 6,029
2021	8,038
2022	8,038
2023	3,467
2024	3,467
2025	3,467
Thereafter	17,332
Intangible assets, net	$ 49,838	$ 51,848

Goodwill (Details)

Goodwill (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 97,307	$ 97,307
Discontinued operations, goodwill	$ 18,623	$ 18,623

Investments Narrative (Details)

Investments Narrative (Details) - USD ($) $ in Thousands		Feb. 28, 2018	Mar. 31, 2020	Mar. 31, 2019	May 31, 2018	Dec. 31, 2015
Schedule of Equity Method Investments [Line Items]
Loss from related party equity method investment	[1]		$ 1,784	$ 2,210
NantOmics
Schedule of Equity Method Investments [Line Items]
Number of A-2 units purchased (in shares)		9,088,362			564,779	169,074,539
Aggregate purchase price						$ 250,774
Ownership percentage					13.58%	14.28%
Difference between the carrying value and equity, intangible assets						$ 28,195
Difference between the carrying value and equity, goodwill						$ 14,382
Loss from related party equity method investment			$ 1,784	$ 2,210
[1]	The statements for the three months ended March 31, 2020 and 2019 include the Connected Care Business (see Note 4).

Investments Summarized Financia

Investments Summarized Financial Information (Details) - NantOmics - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Schedule of Equity Method Investments [Line Items]
Revenues	$ 223	$ 1,746
Gross loss	(1,163)	(520)
Loss from operations	(3,856)	(6,884)
Impairment on equity investments	0	(12,265)
Net loss	(1,360)	(17,851)
Net loss attributable to NantOmics	$ (1,329)	$ (17,752)

Convertible Notes - Narrative (

Convertible Notes - Narrative (Details)	Dec. 21, 2016USD ($)Day$ / shares	Dec. 31, 2016USD ($)	Mar. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Debt Instrument [Line Items]
Number of consecutive trading days trading price evaluated	5 days
Remaining life of convertible notes			21 months
Convertible Debt
Debt Instrument [Line Items]
Face value of debt	$ 107,000,000	$ 107,000,000	$ 107,000,000	$ 107,000,000
Interest rate on debt	5.50%	5.50%
Proceeds from issuance of convertible notes, net of offering costs		$ 102,714,000
Initial purchasers' discount and debt issuance costs	$ 4,286,000	4,286,000
Conversion rate of convertible debt	82.3893
Conversion price of convertible debt (usd per share) | $ / shares	$ 12.14
Threshold of trading days | Day	20
Threshold consecutive trading days | Day	30
Threshold percentage of stock price trigger	120.00%
Business day period trading price evaluated	5 days
Threshold percentage of principal amount	98.00%
Percent of principal	100.00%
Period after conversion date to trigger interest make-whole feature	3 years
Total liability component of convertible notes on date of issuance	$ 83,079,000
Interest make-whole derivative on date of issuance	1,499,000
Carrying value of convertible notes on date of issuance	81,580,000		$ 95,054,000	$ 93,512,000
Conversion option reported in equity as additional paid-in capital	23,921,000
Purchasers' initial discount	972,000
Deferred financing offering costs	$ 3,314,000
Effective interest rate	12.82%
Convertible Debt | Initial Purchasers Agreement
Debt Instrument [Line Items]
Face value of debt		90,000,000
Proceeds from issuance of convertible notes, net of offering costs		92,797,000
Convertible Debt | Cambridge Purchase Agreement
Debt Instrument [Line Items]
Face value of debt		10,000,000
Proceeds from issuance of convertible notes, net of offering costs		9,917,000
Convertible Debt | Pursuant to the exercise of the overallotment by the Initial Purchasers
Debt Instrument [Line Items]
Face value of debt		$ 7,000,000
Convertible Debt | Measurement Input, Discount Rate
Debt Instrument [Line Items]
Discount rate	2.00%

Convertible Notes - Summary of

Convertible Notes - Summary of Issuance of Convertible Debt (Details) - Convertible Debt - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Dec. 21, 2016
Debt Instrument [Line Items]
Gross proceeds	$ 107,000	$ 107,000
Unamortized debt discounts and deferred financing offering costs	(11,946)	(13,488)
Net carrying amount	95,054	93,512	$ 81,580
Related Party
Debt Instrument [Line Items]
Gross proceeds	10,000	10,000
Unamortized debt discounts and deferred financing offering costs	(1,006)	(1,136)
Net carrying amount	8,994	8,864
Others
Debt Instrument [Line Items]
Gross proceeds	97,000	97,000
Unamortized debt discounts and deferred financing offering costs	(10,940)	(12,352)
Net carrying amount	$ 86,060	$ 84,648

Convertible Notes - Interest Ex

Convertible Notes - Interest Expense Incurred (Details) - Convertible Debt - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Debt Instrument [Line Items]
Accrued coupon interest expense	$ 1,471	$ 1,471
Amortization of debt discounts	1,365	1,200
Amortization of deferred financing offering costs	177	157
Total convertible notes interest expense	3,013	2,828
Related Party
Debt Instrument [Line Items]
Accrued coupon interest expense	137	137
Amortization of debt discounts	127	113
Amortization of deferred financing offering costs	3	3
Total convertible notes interest expense	267	253
Others
Debt Instrument [Line Items]
Accrued coupon interest expense	1,334	1,334
Amortization of debt discounts	1,238	1,087
Amortization of deferred financing offering costs	174	154
Total convertible notes interest expense	$ 2,746	$ 2,575

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring basis - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Liabilities
Bookings Commitment	$ 18,854	$ 21,983
Interest make-whole derivative	5	0
Quoted price in active markets for identical assets (Level 1)
Liabilities
Bookings Commitment	0	0
Interest make-whole derivative	0	0
Significant other observable inputs (Level 2)
Liabilities
Bookings Commitment	0	0
Interest make-whole derivative	0	0
Significant unobservable inputs (Level 3)
Liabilities
Bookings Commitment	18,854	21,983
Interest make-whole derivative	$ 5	$ 0

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($)	Dec. 30, 2017	Dec. 21, 2016	Dec. 31, 2016	Mar. 31, 2020	Dec. 31, 2019
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Minimum booking commitments	$ 95,000
Bookings commitment period	10 years
Percentage of shortfall payable	70.00%
Commission percentage	30.00%
Sensitivity analysis, adverse change in discount rate				2.00%
Impact of adverse change in discount rate				$ 2,633,000
Convertible Debt
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Face value of debt		$ 107,000,000	$ 107,000,000	107,000,000	$ 107,000,000
Period to lapse to trigger interest make-whole feature			1 year
Threshold period used to compute interest payment			3 years
Convertible Debt | Measurement Input, Discount Rate
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate		2.00%
Convertible Debt | Convertible Debt, Related Party
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Face value of debt			$ 10,000	$ 10,000,000	$ 10,000,000
Minimum
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cost of debt range used for discounting				18.00%	15.00%
Maximum
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Cost of debt range used for discounting				21.00%	17.00%
Derivative Financial Instruments, Liabilities | Measurement Input, Discount Rate
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Discount rate			2.00%

Fair Value Measurements - Chang

Fair Value Measurements - Changes in the Fair Value of Level 3 Liabilities (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Interest make-whole derivative	$ 21,983
Additions	0
Change in fair value	(3,124)
Interest make-whole derivative	18,859
Interest make-whole derivative - related party and others
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Interest make-whole derivative	0
Additions	0
Change in fair value	5
Interest make-whole derivative	5
Bookings Commitment
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Interest make-whole derivative	21,983
Additions	0
Change in fair value	(3,129)
Interest make-whole derivative	$ 18,854

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Debt (Details) - Convertible Debt - USD ($)	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2016	Dec. 21, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Face Value	$ 107,000,000	$ 107,000,000	$ 107,000,000	$ 107,000,000
Interest rate on debt			5.50%	5.50%
Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value	95,294,000	71,984,000
Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value	95,054,000	93,512,000
Related Party
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Face Value	10,000,000	10,000,000	$ 10,000
Related Party | Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value	$ 8,906,000	6,727,000
Interest rate on debt	5.50%
Related Party | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value	$ 8,994,000	8,864,000
Others
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Face Value	97,000,000	97,000,000
Others | Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value	86,388,000	65,257,000
Others | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair Value	$ 86,060,000	$ 84,648,000

Leases Narrative (Details)

Leases Narrative (Details)	3 Months Ended
	Mar. 31, 2020
Lessee, Lease, Description [Line Items]
Renewal term	5 years
Term for option to terminate leases	1 year
Minimum
Lessee, Lease, Description [Line Items]
Original lease term	1 year
Remaining lease term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Original lease term	11 years
Remaining lease term	10 years

Leases Lease Expense (Details)

Leases Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Operating lease cost	$ 616	$ 598
Short-term lease cost	255	276
Variable cost	78	49
Sublease income	(52)	(52)
Total lease cost	$ 897	$ 871

Leases Additional Operating Lea

Leases Additional Operating Lease Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Leases [Abstract]
Operating cash flows for operating leases	$ (679)	$ (586)
Weighted average remaining lease term - operating leases	5 years 9 months 18 days	6 years 7 months 6 days
Weighted average discount rate - operating leases	11.00%	11.00%

Leases Operating Lease Maturity

Leases Operating Lease Maturity Analysis (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Remainder of 2020	$ 2,040
2021	2,570
2022	2,611
2023	2,652
2024	2,509
2025	656
Thereafter	1,679
Total future minimum lease payments	14,717
Less: imputed interest	(3,840)
Total	10,877
Current operating lease liabilities	1,613	$ 1,617
Noncurrent operating lease liabilities	$ 9,264	$ 9,728

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Dec. 06, 2019	Oct. 23, 2019	Jun. 05, 2019	Apr. 04, 2019	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2016	Dec. 21, 2016	Jan. 04, 2016
Related Party Transaction [Line Items]
Related party promissory note					$ 112,666,000	$ 112,666,000
Litigation settlement		$ 16,500,000
Damages sought	$ 2,900,000		$ 2,300,000	$ 3,000,000
Insurance recoveries					330,000	16,627,000
Affiliated Entity | Promissory Notes With NantCapital
Related Party Transaction [Line Items]
Related party promissory note					138,597,000	136,893,000			$ 112,666,000
Convertible Debt
Related Party Transaction [Line Items]
Face value of debt					$ 107,000,000	$ 107,000,000	$ 107,000,000	$ 107,000,000
Interest rate on debt							5.50%	5.50%

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 93	$ 226
Effective tax rate	1.05%	1.16%

Stockholders_ Equity (Details)

Stockholders’ Equity (Details)	3 Months Ended
	Mar. 31, 2020vote$ / sharesshares	Dec. 31, 2019$ / sharesshares
Equity [Abstract]
Common stock authorized (shares)	750,000,000	750,000,000
Common stock, par value (usd per share) | $ / shares	$ 0.0001	$ 0.0001
Preferred stock authorized (shares)	20,000,000
Preferred stock, par value (usd per share) | $ / shares	$ 0.0001
Number of votes per unit held | vote	1
Preferred stock outstanding (in shares)	0	0

Stock-Based Compensation Compon

Stock-Based Compensation Components of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Amount capitalized to internal-use software	$ 19	$ 57
Total stock-based compensation cost	672	707
Phantom units:
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	42	20
Phantom units: | Cost of revenue
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	16	19
Phantom units: | Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	9	16
Phantom units: | Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	17	(15)
Stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	276	0
Stock options | Cost of revenue
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	15	0
Stock options | Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	237	0
Stock options | Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	24	0
Restricted stock units:
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	414	605
Restricted stock units: | Cost of revenue
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	7	3
Restricted stock units: | Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	389	592
Restricted stock units: | Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	18	10
Continuing and Discontinued Operations
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	653	650
Discontinued operations
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ (79)	$ 25

Stock-Based Compensation Narrat

Stock-Based Compensation Narrative (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Unvested phantom units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense expected to be recognized	$ 46
Period for recognition of compensation cost not yet recognized	2 months 12 days
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period for recognition of compensation cost not yet recognized	2 years 3 months 18 days
Unrecognized stock based compensation	$ 1,270
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock based compensation	$ 610
Weighted average term for recognition of compensation expense	7 months 6 days

Stock-Based Compensation Activi

Stock-Based Compensation Activity of Phantom Units (Details) - Unvested phantom units	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Number of Units
Unvested units outstanding, beginning balance (units) | shares	120,562
Forfeited (in units) | shares	(5,454)
Unvested units outstanding, ending balance (units) | shares	115,108
Weighted- Average Grant Date Value Per Phantom Unit
Unvested units outstanding, beginning balance (usd per unit) | $ / shares	$ 11.49
Forfeited (usd per unit) | $ / shares	14.24
Unvested units outstanding, ending balance (usd per unit) | $ / shares	$ 11.38

Stock-Based Compensation Acti_2

Stock-Based Compensation Activity of Stock based Compensation Units (Details)	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Number of Shares
Stock options outstanding, beginning balance (in shares) | shares	5,815,724
Forfeited (in shares) | shares	(270,000)
Stock options outstanding, ending balance (in shares) | shares	5,545,724
Stock options exercisable - March 31, 2020 (in shares) | shares	137,500
Weighted-Average Exercise Price
Stock options outstanding, beginning balance (in dollars per share) | $ / shares	$ 0.56
Forfeited (in dollars per share) | $ / shares	0.55
Stock options outstanding, ending balance (in dollars per share) | $ / shares	0.56
Stock options exercisable - March 31, 2020 (in dollars per share) | $ / shares	$ 0.55

Stock-Based Compensation Acti_3

Stock-Based Compensation Activity of Restricted Stock Units (Details) - Restricted Stock Units	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Number of Units
Unvested units outstanding, beginning balance (units) | shares	705,415
Granted (in units) | shares	179,558
Forfeited (in units) | shares	(10,954)
Unvested units outstanding, ending balance (units) | shares	874,019
Weighted-Average Grant Date Fair Value
Unvested units outstanding, beginning balance (usd per unit) | $ / shares	$ 2.68
Granted (usd per units) | $ / shares	1.81
Forfeited (usd per unit) | $ / shares	3.39
Unvested units outstanding, ending balance (usd per unit) | $ / shares	$ 2.49

Net Income (Loss) Per Share Rec

Net Income (Loss) Per Share Reconciliations of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended
		Mar. 31, 2020	Mar. 31, 2019
Net income (loss) per share numerator:
Net loss from continuing operations		$ (8,940)	$ (19,635)
Net income (loss) from discontinued operations		32,005	(288)
Net income (loss)	[1]	$ 23,065	$ (19,923)
Weighted Average Number of Shares
Weighted-average shares for basic net income (loss) per share (shares)		110,619,780	109,904,336
Effect of dilutive securities (shares)		0	0
Weighted-average shares for dilutive net income (loss) per share (shares)		110,619,780	109,904,336
Basic and diluted net income (loss) per share
Continuing operations - common stock (in usd per share)		$ (0.08)	$ (0.18)
Discontinued operations - common stock (in usd per share)		0.29	0
Total net income (loss) per share - common stock (in usd per share)		$ 0.21	$ (0.18)
[1]	The statements for the three months ended March 31, 2020 and 2019 include the Connected Care Business (see Note 4).

Net Income (Loss) Per Share Ant

Net Income (Loss) Per Share Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Unvested restricted stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	0	1
Unvested phantom units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	115,108	283,862
Unvested restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	874,019	1,790,182
Unexercised stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	5,545,724	0
Convertible notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	8,815,655	8,815,655

Related Party Transactions (De

Related Party Transactions (Details)	Aug. 08, 2018USD ($)	Jun. 01, 2016USD ($)shares	Mar. 08, 2016USD ($)	Jan. 22, 2016USD ($)	Jan. 04, 2016USD ($)$ / shares	Jun. 19, 2015USD ($)termtest	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2016USD ($)	Dec. 21, 2016USD ($)	Dec. 15, 2016USD ($)
Related Party Transaction [Line Items]
Related party receivables							$ 1,931,000		$ 1,931,000
Related party payables, net of receivables balances including related party liabilities							30,483,000		28,347,000
Related party promissory note							112,666,000		112,666,000
Convertible Debt
Related Party Transaction [Line Items]
Face value of debt							107,000,000		107,000,000	$ 107,000,000	$ 107,000,000
Receivable from Ziosoft KK related to sale of Qi Imaging | Affiliated Entity
Related Party Transaction [Line Items]
Related party receivables							1,658,000		1,658,000
Reseller agreement
Related Party Transaction [Line Items]
Term of agreement with related party						5 years 6 months
Reseller agreement | Equity Method Investee
Related Party Transaction [Line Items]
Number of renewals | term						3
Renewal term						3 years
Number of tests to qualify for first renewal option | test						300,000
Number of tests to qualify for second renewal option | test						570,000
Number of tests to qualify for third renewal option | test						760,000
Renewal option if threshold unmet, nonexclusive, number of years						3 years
Annual minimum fees, tier one						$ 2,000,000
Annual minimum fees, tier two						25,000,000
Annual minimum fees, tier three						$ 50,000,000
Related party payables							108,000		197,000
Cost of revenue							36,000	$ 1,068,000
Cambridge Purchase Agreement | Affiliated Entity | Convertible Debt
Related Party Transaction [Line Items]
Face value of debt												$ 10,000,000
Accrued and unpaid interest on convertible notes							162,000		24,000
Liquid Tumor Profiling Services Agreement
Related Party Transaction [Line Items]
Related party receivables							110,000		110,000
Revenue from related parties							0	349,000
Promissory Notes With NantCapital | Affiliated Entity
Related Party Transaction [Line Items]
Accrued and unpaid interest on convertible notes							25,931,000		24,227,000
Related party promissory note					$ 112,666,000		138,597,000		$ 136,893,000
Interest bearing on related promissory note					5.00%
Per share price of stock shares to repay debt (usd per share) | $ / shares					$ 18.6126
Per share price of shares to settle debt (usd per share) | $ / shares					$ 1.484
Promissory Notes With NantOmics | Equity Method Investee
Related Party Transaction [Line Items]
Related party promissory note				$ 20,000,000			0
Interest bearing on related promissory note				5.00%
Additional advance on related party promissory note			$ 20,000,000
Amount of principal and interest under promissory note converted to shares		$ 40,590,000
Number of shares related party promissory note converted (in shares) | shares		2,899,297
Promissory Note 9.75%, Due June 15, 2022 | Affiliated Entity
Related Party Transaction [Line Items]
Related party promissory note	$ 100,000,000
Interest bearing on related promissory note	9.75%
Maximum advances available through March 2019	$ 10,000,000
Maximum advances available after March 2019 until maturity	$ 20,000,000
Percentage profit measure deviation allowed	25.00%
NantWorks | Shared services agreement | Affiliated Entity
Related Party Transaction [Line Items]
Net selling, general, and administrative service expenses incurred related to services provided by related parties							$ 486,000	$ 574,000